CUMULATIVE INDEX 1993

Volume 40

February	CHILDHOOD HYPERTENSION, pages 1–219
April	TRANSPORT MEDICINE, pages 221–463
June	THE CHILD WITH DEVELOPMENTAL DISABILITIES, pages 465–692
August	PEDIATRIC OPHTHALMOLOGY, pages 693–896
October	UPDATE ON NEONATOLOGY, pages 897–1120
December	PEDIATRIC SURGERY, pages 1121–1402

Note: Page numbers of issue and article titles are in **boldface** type

Aarskog syndrome, ptosis with, 798
Abandonment, concept of, in critical care transport, 255
Abdominal aorta, coarctation of, and renal artery narrowing, 124
Abdominal trauma, transport and stabilization in, 372
Abdominal tumors, in infancy and childhood, **1253–1271**
Abdominal wall defects, as newborn surgical emergency, 1307–1312
Abduction, examination of, in cerebral palsy, 647
Abrasions, from birth trauma, 1353
Academic achievement, with learning disabilities, testing for, 499
Accommodation, deficient, glasses for, 671
Accommodative insufficiency, school complaints with, 763
Acebutalol, properties of, 202
Acetaminophen, acute poisoning with, management of, 408–410
N-Acetylcysteine, for acetaminophen poisoning, 410
Achilles tendon, contracture of, in cerebral palsy, orthopedic intervention for, 655
Achromatopsia, and infant blindness, 778–779
Acidosis, metabolic, in salicylate intoxication, 412
Activities, repertoire of, in autism, 569
Adaptive equipment, for developmental disabilities, 632
Adenoma, hepatic, in infancy and childhood, 1265–1266
Adolescents, obesity in, and cardiovascular risk, 87–88
  and hypertension, **81–92**
    effect of weight loss on, 83
  treatment of, 88–90
Adrenal, congenital hyperplasia of, neonatal screening for, 1087–1088
  injury to, from birth trauma, 1355–1356
  tumor of, in child, 1262
Adrenal cortex, disorders of, and hypertension, 151–153, 160
Adrenal steroid pathway, 155
Adrenergic nervous system, drugs affecting, for childhood hypertension, 201
Adult respiratory distress syndrome, surfactant replacement therapy for, 930
Aerobic conditioning, for hypertension, in insulin-dependent diabetes mellitus, 100
Aerosol therapy, for upper airway obstruction, during transport, 268
Aggression, with developmental disabilities, 583–584
Air transport, **439–456**
  communications in, 448
  costs in, 448–449, 452
  equipment for, 446–447
  history of, 439–440
  organizations involved in, 454–455

Air transport *(Continued)*
patient evaluation and stabilization for, 450–454
patients carried by, 440
program structure in, 440–447
quality assurance for, 447–450
team composition for, 444–445
training for, 445
vehicles for, 440–444
advantages and disadvantages of, 250
fixed-wing aircraft, 443–444, 448
helicopters, 442–443, 448
mileage and time to patient with, 450
mileage and time to receiving facility with, 451
selection of, 449–450
Airway(s), in diabetic ketoacidosis, stabilization and management of, 357
in neonatal cardiopulmonary resuscitation, 293–294
in neurologically compromised child, 344–345
management of, for transport, **381–406**
establishment of, 384–400
initial evaluation in, 382
therapeutic interventions in, 382–384
bag and mask airway assistance, 383–384
oxygen administration, 382–383
relieving upper airway obstruction, 383
obstruction of, interhospital transport with, 268–269, 383
oral, pediatric sizes of, 376
protective reflexes of, loss of, intubation for, 385
resistance of, effect of edema on, 385
stabilization of, for air transport, 451
in trauma patient, 366–368
trauma to, in high-frequency ventilation, 987
Ala nasi, arteriovenous malformation of, 1197
Alagille's syndrome, in newborn, and jaundice, 1166
Albinism, and infant blindness, 778–779
Albuminuria, and hypertension, in insulin-dependent diabetes mellitus, 95
Alcohols, intoxication with, 418–420
Aldosterone, elevated, and hypertension, 152
Alfentanil, intubation with, 388–389
Allergic manifestations, in extreme prematurity, 942
Alpha-adrenergic blocking drugs, for hypertension, 204–205
Alpha$_1$-antitrypsin, deficiency of, in newborn, and jaundice, 1165
Alpha-fetoprotein, maternal, serum, in pregnancy screening for surgical anomalies, 1274
Alport syndrome, and cataracts, 842
Alprazolam, for increased muscle tone, 598–599
Altitudes, temperature and pressure at, 453
Amblyopia, **727–735**
deprivation, 728–729
diagnosis of, 727–728
etiology of, 728–730
examination for, 730–731
in children, and sports participation, 837–838
in visual development, 660–661
organic, 730
prognosis in, 734
refractive, 730
strabismic, 729
treatment of, 731–734
types of, 729
Ambulance, for neonates, 222
ground, advantages and disadvantages of, 250
cost of, 452
mileage and time to patient with, 450
mileage and time to receiving facility with, 451
incubator for, 230
American Academy of Pediatrics Neonatal Resuscitation Program, guidelines of, 432
American Heart Association, guidelines for neonatal advanced life support, 431
Amniocentesis, in antenatal detection of surgical anomalies, 1276–1277
Amnioinfusion, in meconium staining, 967
Amniotic fluid, aspiration pneumonia caused by, surfactant replacement therapy for, 930
biochemical screening of, in antenatal detection of surgical anomalies, 1278–1279
color of, and timing of meconium staining, 969
Amphetamines, for attention-deficit hyperactivity disorder, 606
Anabolic steroids, and hypertension, 157, 160
Anemia, shock in, 305
Angioedema, and eyelid edema, 792–793
Angiography, digital subtraction, for renal artery stenosis diagnosis, 134–136
intravenous, in persistent hypertension, 173
Angiokeratoma, 1193
Angioplasty, percutaneous transluminal, for persistent hypertension, 176

for renovascular hypertension, 135–137
Angiotensin, in renin-angiotensin cascade, 62, 64–65
Angiotensin-converting enzyme, in renin-angiotensin cascade, 62, 65
Angiotensin-converting enzyme inhibitor(s), challenge test with, for renal artery stenosis diagnosis, 132
for hypertension, in insulin-dependent diabetes mellitus, 100
renin-angiotensin system associated, 73–74
Angiotensin receptors, in renin-angiotensin cascade, 62, 65–66
Angiotensinase, in renin-angiotensin cascade, 62, 66
Angiotensinogen, in renin-angiotensin cascade, 61–62
Aniridia, secondary glaucoma with, 862–863
Ankle, musculoskeletal examination of, in cerebral palsy, 652
Anorectal malformations, as newborn surgical emergency, 1301–1305
associated defects with, 1303
embryology of, 1302
evaluation of, 1303–1304
management of, 1304–1305
outcome in, 1305
pathology of, 1302–1303
Antibiotics, for nasolacrimal duct infection, 775
Anticholinergic agents, for dystonia, 603
Anticonvulsants, for seizure patients, during transport, 270
Antihistamines, topical, for conjunctivitis, 761
Antihypertensive drugs, dosages for children, 207–208
in infancy, 118
Antireflux procedure, for gastroesophageal reflux, alternatives to, 1246–1248
outcome and prognosis of, 1248
with gastrostomy, 1246
Anxiety, with developmental disabilities, 584–585
Aorta, coarctation of, and hypertension, in infancy, 111–112
renin-angiotensin system in, 72
blood pressure and lipids in, 47
Aortic insufficiency, and systemic hypertension, 145
Aortorenal bypass, for renovascular hypertension, 137–138
Apgar score(s), and need for cardiopulmonary resuscitation, 292
and neonatal resuscitation, 433
distribution of, 292
zero, outcome with, 299
Aphakia, correction for, following cataract removal, 849
Apnea, and sudden death, **897–911**
home monitoring of, for sudden infant death syndrome, 904–905
in drowning, 326–327
intubation for, 385–386
of prematurity, and sudden infant death syndrome, 906–907
Apparent life-threatening events, in sudden infant death syndrome, 900–906. See also *Life-threatening events.*
Appendicitis, **1201–1211**
clinical presentation of, 1204–1206
diagnostic evaluation of, 1207–1208
differential diagnosis of, 1205–1206
epidemiology of, 1202–1203
history of, 1201–1202
management of, 1208–1209
pathophysiology of, 1203–1204
physical examination in, 1206
Arm, capillary-lymphatic lesions of, 1193
Arterial baroreflex, regulation of, renin-angiotensin system and, 69
Arterial blood gases, in intubated patient, during transport, 271
Arterial malformations, 1196–1197
Arteriography, renal, selective, in persistent hypertension, 174–176
Arteriohepatic dysplasia, in newborn, and jaundice, 1166
Arteriovenous fistula, and systemic hypertension, 145
Arteriovenous malformation, of ala nasi, 1196
Asphyxia, and cerebral palsy, 540
damage caused by, in meconium aspiration syndrome, 960–961
near total, and hypoxic-ischemic brain damage, 1067–1070
partial, and hypoxic-ischemic brain damage, 1062–1067
perinatal, and developmental disability, 483–484
Aspiration, with drowning, 328
definition of, 321
type of fluid, 328–330
Aspiration pneumonia, in neonate, surfactant replacement therapy for, 930
Association of Air Medical Services, air transport by, 454
Asthma, intubation with, 394
patients with, interhospital transport of, 269
Astigmatism, glasses for, 670
school complaints with, 763
Astrocytoma, pilocytic, juvenile, of orbit, 824

Atenolol, properties of, 202
Atherosclerosis, in childhood hypertension, 55–56
  pathogenesis of, 42
Athetosis, with developmental disabilities, treatment of, 599–603
Atopic conjunctivitis, and eyelid edema, 792
Atopic dermatitis, and cataracts, 842
Atracurium, intubation with, 391–392
Attention deficit(s), with developmental disabilities, 583
Attention-deficit disorder, without hyperactivity, stimulants for, 607
Attention-deficit hyperactivity disorder, with anxiety/depression, stimulants for, 607–608
  with developmental disabilities, pharmacology in, 605–606
    stimulants for, nonresponders to, 608
  with externalizing disorder, stimulants for, 608
  with learning disabilities, 496
  with tics, stimulants for, 607
Autism, **567–578**
  assessment of, 573
  clinical features of, 570
  deficits associated with, 571–572
  diagnostic criteria for, 568–569
  differential diagnosis of, 571
  history of, 567–568
  intervention in, 573–575
  outcome in, 575–576
  pathogenesis of, 570–571
  with developmental disabilities, 586
Aviation physiology, in shock patient transport, 313–314
Avoidance behavior, in vision assessment, 696
Azathioprine, in heart transplantation, 1034

Baclofen, for increased muscle tone, 599
  in developmental disabilities, 594
Bacterial conjunctivitis, ophthalmia neonatorum vs, 716–719
Bacterial infections, in newborn, and jaundice, 1167
Bacterial meningitis, neurological compromise with, 343
Bacterial toxins, gastrointestinal, and necrotizing enterocolitis, 1050–1051
Bag and mask airway assistance, in transport, 383–384
Bag-valve mask, pediatric sizes of, 376
Barbiturates, intubation with, 387–388
Baroreceptor mechanisms, in renin-angiotensin system, 67
Basal cell carcinoma, of eyelid, 809–810
Bayes' formula, for decision making, 1019
BCG vaccination, complications of, 1100
  of infant with tuberculosis, 1096
Behavior, analysis by pediatricians, in developmental disabilities, 617–619
  disorders of, with autism, 572
    with mental retardation, clinical issues in, 580–581
  disturbances of, with learning disabilities, 496–497
  management of, in developmental disabilities, **617–628**
    outcome of, 626–627
    techniques of, 619–626
    in psychiatric disorders with developmental disabilities, 590
    techniques of, with learning disabilities, 501
  problems with, in cerebral palsy, 544
    in traumatic brain injury, 560
Behavior change, in adolescent obesity treatment, 89
Behavioral treatment, in autism, 574–575
Benzodiazepines, for increased muscle tone, 598–599
  intubation with, 388–389
Benzotropin mesylate, in developmental disabilities, 594
Beta-adrenergic agonists, for persistent pulmonary hypertension of newborn, 988
Beta-adrenergic blocking drugs, adverse effects of, 204
  for childhood hypertension, 201–204
  properties of, 202
Bicycle injuries, in pediatric population, 1362–1363
Bile duct, spontaneous perforation of, in newborn, and jaundice, 1171
Bile plug syndrome, in newborn, and jaundice, 1171–1172
Biliary atresia, in newborn, and jaundice, 1168–1170
Binocular vision, development of, 737–738
Biochemical abnormalities, and cerebral palsy, 541
Biochemical genetics, in antenatal detection of surgical anomalies, 1279
Biotinidase deficiency, neonatal screening for, 1080
Birth control pills, and hypertension, 157, 160
Birth trauma, **1351–1358**
Birthweight, and blood pressure, 110
  and delivery hospital, 291
Blepharochalasis syndrome, and eyelid edema, 793
Blepharophimosis, ptosis with, 798–799

Blepharoptosis, 797
Blepharospasm, with infantile glaucoma, 856
Blind children, education of, 885–887
Blindness, in extreme prematurity, 941
  in infancy, 777–780
Blinking, ocular disorders with, 763–764
Blood, loss of, system responses to, 369
  transfusion of, in shock, 309
Blood aspiration pneumonia, surfactant replacement therapy for, 930
Blood pressure, adult, high, childhood predictors for, **23–40**
  age-specific percentiles of, 108
  birthweight and, 110
  bivariate genetic analysis of, 9
  childhood, and essential hypertension risk, 179–180
    determinants of, 180–184
    elevated, identification and treatment of, 189
    racial aspects of, **13–22**
    regulation of, renin-angiotensin system and, **61–79**
    relationship to lipids, **41–49**
  familial aggregation of, 3–4
  interaction with insulin and lipids, 44–45
  racial differences in, meta-analysis of, 13–19
      discussion of, 16–19
      results of, 14–16
      statistical methodology of, 13–14
  regulation of, sex differences in, 7–8
  relationship to lipids, lifestyle factors in, 45–46
  twin studies of, 5–10
Blood pressure cuff, pediatric sizes of, 376
Blue rubber bleb nevus syndrome, of foot, 1198
Body mass index, bivariate genetic analysis of, 9
Body size, in children, and blood pressure, 37
Body temperature, control of, during transport, 273
Bone, fluid infusion in, in shock, 307
Bowel, normal, anatomic development of, 1335–1336
Bowel disease, inflammatory, **1213–1231**. See also *Inflammatory bowel disease.*
Brachial plexus palsy, from birth trauma, 1351–1353
Bradycardia, home monitoring of, for sudden infant death syndrome, 904–905
Brain damage, hypoxic-ischemic, **1061–1072**
    concept of selective vulnerability in, 1070–1071
    near total asphyxia and, case study of, 1069–1070
      imaging in, 1069
      in experimental animals, 1067–1068
      neonatal clinical picture in, 1068–1069
    partial asphyxia and, 1062–1067
      case study of, 1065–1067
      computed tomography of, 1065–1066
      imaging in, 1064–1065
      in experimental animals, 1062–1063
      neonatal clinical picture in, 1063–1064
  prevention of, neonatal resuscitation for, 433
Brain death, in drowning, pathophysiology of, 325
Brain imaging studies, in developmental delay, 473–474
Brain injury, traumatic, **553–565**
    and visual problems, 663
    computed tomography of, 556
    epidemiology of, 553–554
    intraaxial, 555
    management of, acute, 557
    neurorehabilitation in, 558–561
    outcome in, predictors of, 561–562
    prevention of, 562–563
    recovery from coma in, 557–558
    rehabilitation therapy for, 636–637
    severity of, 554–557
    types of, 554
Branchial remnants, 1153
Break point, in drowning, 327
Breast milk, for preterm neonate, 1106
Breath-holding spells, 908
Breathing, control of, in extremely low birthweight infant, 946
  in neurologically compromised child, 344–345
  in trauma patient, stabilization of, 366, 368
Bronchiolitis, patients with, interhospital transport of, 269
Bronchopulmonary dysplasia, and developmental disability, 485
  and hypertension, in infancy, 112
  effect of surfactant replacement therapy on, 925–927
  etiology of, 926
  incidence of, 926
Bronchospasm, patients with, interhospital transport of, 269
Brown syndrome, strabismus with, 750–751
Buckle procedures, for retinopathy of prematurity, 711–712
Bundesen, Herman, and Chicago premature infant care, 232–233

Bupropion, for attention-deficit hyperactivity disorder, 611
Burns, in pediatric patient, estimation of extent of, 374
injuries from, in pediatric population, 1363–1364
transport and stabilization in, 373
Buspirone, for attention-deficit hyperactivity disorder, 611

Calcium, dietary, and childhood blood pressure, 182
Calcium channel blockers, for hypertension, 198–200
in insulin-dependent diabetes mellitus, 100
for persistent pulmonary hypertension of newborn, 988
Cancer, inflammatory bowel disease and, 1227–1228
Capillary hemangioma, of eyelid, 808
of orbit, 822
Capillary malformations, 1190–1194
Capillary-lymphatic malformation, 1192–1193
Capillary-lymphatico-venous anomaly, combined, of leg, 1198
Capreomycin, for tuberculosis in infancy, 1096
Capsulectomy, posterior, in pediatric cataract removal, 848
Captopril, for hypertension, 195–198
effect on diabetic nephropathy, 98–100
in infancy, 117–118
renin-angiotensin system associated, 73
Carbon dioxide, effect on cerebral blood flow, 341
Cardiac arrest, intubation for, 386
Cardiac dysrhythmias, in diabetic ketoacidosis, stabilization and management of, 358
Cardiac massage, in infants, morbidity and mortality in, 289–290
Cardiac output, in shock, pre-transport augmentation of, 307
Cardiac transplantation. See *Heart transplantation.*
Cardiomyopathy, neonatal, heart transplantation for, 1027
Cardiopulmonary resuscitation, in newborns, airway and, 293
application to transport medicine, **287–302**
assessment for, 292–293
environment and, 293
ethical dilemmas in, 297–299
hospital capabilities for, 300
intubation and, 294–296
medications for, 296–298
morbidity and mortality in, 290
outreach education for, 299–300
prediction of need for, 287–291
preparation for, 292
ventilation and, 293–294
Cardiovascular causes, of systemic hypertension, **141–147**
Cardiovascular function, modulation of, renin-angiotensin system and, 69
Cardiovascular manifestations, of hypertension, **51–59**
Cardiovascular reactivity, racial differences in, 17
Cardiovascular risk, in adolescent obesity, 87–88
Carotid artery ligation, in extracorporeal membrane oxygenation, risk from, 1012
Cat scratch disease, and cervical lymphadenopathy, 1154
Cataracts, **841–853**
clinical anatomy and embryology of, 841–845
clinical correlations with, 841–845
clinical presentation of, 845
congenital, ocular disorders associated with, 847
etiology and classification of, 845–847
management of, 847–850
postoperative, 849–850
preoperative evaluation, 847–848
surgery, 848
posterior subcapsular, appearance of, 843
screening technique for, 845
Cathartics, for tricyclic antidepressant intoxication, 415
Cavernous hemangioma, in infancy and childhood, 1265
Central nervous system, infection of, and developmental disability, 484–485
neuroimaging findings in, 474
involvement of, in tuberculosis in infancy, 1090
osmolal environment of, in neurologically compromised child, 339–340
trauma to, transport and stabilization in, 371
Cephalohematoma, of scalp, 1159
Cerebral blood flow, control of, in neurologically compromised child, 340–341
Cerebral edema, in diabetic ketoacidosis, fluid resuscitation in, 348
stabilization and management of, 358–360
in near-drowning, 330

in neurologically compromised child, 341–342
management of, 347
Cerebral palsy, **537–551**
assessment of, 544–546
classification system for, 537–538
deficits associated with, 543–544
differential diagnosis of, 543
early identification of, 542–543
etiology of, 539–542
asphyxia, 540
biochemical abnormalities, 541
congenital infections, 542
environmental toxins, 541–542
genetic causes, 541
postnatal events, 542
prematurity, 539–540
prenatal abnormalities, 540–541
gait analysis in, 654
in extreme prematurity, 941
intervention in, approaches to, 546–548
orthopedic management of, **645–657**
outcome in, 548
prevalance of, 538–539
psychiatric disorders with, 587
radiographic assessment in, 654
rehabilitation therapy for, 635–636
Cerebral perfusion, stabilization of, in air transport, 452–453
Cerebrovascular autoregulation, in neurologically compromised child, 340–341
Cervical collars, pediatric sizes of, 376
Cheek, venous malformation of, 1194
Chemical conjunctivitis, ophthalmia neonatorum vs, 716–717
Chest, minor anomalies of, syndromes associated with, 469
Chest compressions, for newborns, 296
Chest physiotherapy, for meconium aspiration syndrome, 971
Chest tube(s), patient with, interhospital transport of, 272
pediatric sizes of, 376
Child advocacy, in developmental disabilities, 679, 682–683
Child interview, in behavior analysis in developmental disabilities, 618–619
Children, failed vision test in, preschool, 755
preverbal, 754–755
school-aged, 755–756
glaucoma in, **855–867**. See also *Glaucoma.*
ocular signs and symptoms in, **753–766**
ocular tumors of, **805–826**
vision development in, **693–703**
Children's Bureau, and standards for neonatal care, 235
Chlamydial conjunctivitis, ophthalmia neonatorum vs, 716, 719–720
Chlorothiazide, for hypertension, in infancy, 118
Choledochal cyst, in newborn, and jaundice, 1171–1172
Cholestasis, with total parenteral nutrition, in newborn, and jaundice, 1166–1167
Chorea, with developmental disabilities, treatment of, 599–603
Chorionic gonadotropin, human, for cryptorchidism, 1137
Chorionic villus sampling, in antenatal detection of surgical anomalies, 1277
Choristoma, conjunctival, 811
Choroidal hemangioma, 818
Choroidal nevus, 819–820
Choroidal osteoma, 818–819
Chromosomal karyotyping, in developmental delay, 472–473
Chylothorax, from birth trauma, 1354
Ciliary body, medulloepithelioma of, 817–818
Cimetidine, for short bowel syndrome, 1339
Circulation, in diabetic ketoacidosis, stabilization and management of, 357–358
in neurologically compromised child, 344–345
stabilization of, in air transport, 452
in trauma patient, 366, 368–370
Clomipramine, for attention-deficit hyperactivity disorder, 611
Clonazepam, for increased muscle tone, 598–599
Clonidine, for attention-deficit hyperactivity disorder, 610
for childhood hypertension, 205
for Tourette syndrome, 601–602
in developmental disabilities, 594
Clozapine, for self-injurious behavior, with developmental disabilities, 604
Coarctation of aorta, and hypertension, in infancy, 111–112
renin-angiotensin system in, 72
systemic, 141–145
diagnosis of, 141–142
management of, 142
mechanisms of, 143–145
blood pressure and lipids in, 47
Cognitive deficits, in traumatic brain injury, 559–560
Cognitive development, in extreme prematurity, 941
Cognitive potential, with learning disabilities, testing for, 498–499
Colic, in preterm neonate, 1107

Collis-Nissen fundoplication, for gastroesophageal reflux, 1243–1245
Colloids, infusion of, in shock, 308
Coma, in traumatic brain injury, recovery from, 557–558
Communication, deficits of, in traumatic brain injury, 559
  disorders of, with autism, 569, 572
  systems for, in critical care transport, 251
Computed tomography, for persistent hypertension, 169
Computer aids, for visually impaired, 889
Congenital abnormalities, and visual problems, 661–662
  with developmental disability, 484
    examination for, 468
Congenital heart lesions, interhospital transport for, 264
Congenital infection, and cerebral palsy, 542
  and developmental disability, 484–485
Congestive heart failure, in renovascular hypertension, 125
Conjunctiva, injuries to, initial management of, 830–831
  tumors of, 810–813
    clinical signs of, 805–806
    diagnostic approaches to, 807
    therapeutic approaches to, 807
Conjunctivitis, allergic, 759
  and eyelid edema, 791–792
  bacterial, ophthalmia neonatorum vs, 716–719
    signs and symptoms of, 757–758
  chemical, ophthalmia neonatorum vs, 716–717
  childhood, signs and symptoms of, 757–760
    treatment of, 760–761
  chlamydial, ophthalmia neonatorum vs, 716, 719–720
    signs and symptoms of, 758
  contact, and eyelid edema, 792
  herpes simplex, signs and symptoms of, 758–759
  neonatal, signs and symptoms of, 756–757
    treatment of, 757
  red eye with, 756–761
  viral, ophthalmia neonatorum vs, 716, 720–721
Contact conjunctivitis, and eyelid edema, 792
Contact lenses, for aphakia correction, following cataract removal, 849–850
Convergence insufficiency, and headache, 762
Converting enzyme inhibitors, for childhood hypertension, 195–198
Coping skills, in developmental disabilities, 675–676
Cordocentesis, in antenatal detection of surgical anomalies, 1277–1278
Cornea, edema of, with infantile glaucoma, 858
  enlargement of, with infantile glaucoma, 856, 858
  foreign bodies in, removal of, 832
  haziness of, with infantile glaucoma, 856
  injuries to, initial management of, 831–832
Corneal light reflex tests, for diagnosis of strabismus, 738–739
Coronary artery disease, of graft, in heart transplantation, 1039
Coronary heart disease, risk for, with childhood high blood pressure, 37–38
Cortical blindness, in infancy, 780
Cortical pathways, in vision development, 694–695
Corticosteroids, for inflammatory bowel disease, 1221–1222
  for necrotizing enterocolitis prevention, 1053–1055
  for optic neuritis, 785
  in heart transplantation, 1034
  in neurologically compromised child, indications for, 350
  systemic, for hemangiomas, 1186
Cortisol, elevated, and hypertension, 151–152
Cough, in tuberculosis in infancy, 1089
Counseling, in antenatal detection of surgical anomalies, 1282–1284
    decision making in, 1284
    providers of, 1282–1283
    recipients of, 1283
    technique of, 1283–1284
    timing of, 1283
  with learning disabilities, 501
Cranial nerve palsies, and paretic strabismus, 787
Craniofacial anomalies, neuroimaging findings in, 474
Craniopharyngioma, and visual loss, 784–785
Cricoid pressure, in intubation, 395
Cricothyrotomy, with intubation, 399–400
Crigler-Najjar syndrome, in newborn, 1163–1164
Crohn's disease, **1213–1231**. See also *Inflammatory bowel disease.*
Cryotherapy, for retinopathy of prematurity, 711
Cryptorchidism, **1133–1149**
  complications of, 1140
  embryology of descent in, 1135–1136
  endocrine aspect of, 1136–1137

hormonal treatment of, 1137–1138
incidence of, 1135
position of testis in, 1134
surgical treatment of, 1138–1140
Crystalloids, infusion of, in shock, 308
Cushing's syndrome, and hypertension, 156, 160
Cutaneous hemangioma, 1200
Cutis mamorata telangiectasia congenita, 1192
Cycloserine, for tuberculosis in infancy, 1096
Cyclosporine, in heart transplantation, 1034–1035
Cystic fibrosis, in newborn, and jaundice, 1164–1165
neonatal screening for, 1082–1083
Cystic hygroma, of neck, 1156
Cystic renal disease, in persistent hypertension, 171
Cytogenetics, in antenatal detection of surgical anomalies, 1279–1280
Cytomegalovirus infection, in heart transplantation, 1040
in newborn, and jaundice, 1168

Dacrocystorhinostomy, for nasolacrimal duct obstruction, 776
Dantrolene, for increased muscle tone, 599
in developmental disabilities, 594
Deferoxamine, for iron poisoning, 417
Delayed maturation, and reading failure, 870–871
DeLee, Joseph Bolivar, transport incubator invention by, 229–231
Delivery room, resuscitation in, overview of, 295
procedures for, 288–289
Dementia, with developmental disabilities, 584
Dental problems, with Down syndrome, 527
Depression, with developmental disabilities, 581
Deprivation amblyopia, 728–729
treatment of, 731
Dermatomyositis, and eyelid edema, 793
Dermoid, conjunctival, 810–811
Dermoid cyst, of orbit, 821–823
of scalp, 1159
Descemet's membrane, rupture of, with infantile glaucoma, 858
Desipramine, for attention-deficit hyperactivity disorder, 609–610
in developmental disabilities, 594
Desmarre retractor, for conjunctival injuries, 831
Developmental anomalies, minor, syndromes associated with, 469
Developmental delay, assessment of, **465–477**
coordination of care in, 475
early identification of, 465–466
medical testing in, 472–475
brain imaging studies, 473–474
chromosomal karyotyping, 472–473
electroencephalogram, 473
metabolic screening, 474–475
mental retardation vs, 517
neurodevelopmental assessment of, 466–472
developmental history, 466–467
developmental screening, 471–472
hearing and vision screening, 467, 470
neurologic examination, 470–471
physical examination, 467–469
Developmental disability(ies), adult issues in, 679–680
aggression with, 583–584
anxiety with, 584–585
attention deficits with, 583
autism with, 586
behavior management in, **617–628**. See also *Behavior management*.
child advocacy in, 679, 682–683
coping with, 675–676
dementia with, 584
depression with, 581–582
dual diagnoses in, **579–592**
early intervention for, implications of, 486–488
education in, 678–679
Federal legislation for, 467
family survival in, 676–677
hyperactivity with, 583
identification of, 479–480
rates of, 466
mania with, 581–582
medical care in, 678–679
mobility and adaptive equipment for, 632
neurodevelopmental therapy for, 630–631
orthotics for, 631–632
parenting skills in, 677
personal account of, **675–683**
pharmacology in, **593–616**
pharmacotherapy for, issues in, 612–613
physical and occupational therapy for, 632–633
psychiatric disorders in, **579–592**
psychosis with, 581–583
rehabilitation for, **629–643**
resources and agencies in, 678
risk factors for, 480–486
biologic, 480–485

Developmental disability(ies) *(Continued)*
environmental, 486
self-injurious behavior with, 585–586
sharing responsibility in, 677–678
somatoform disorders with, 585
stereotypy with, 585–586
visual function in, **659–674**. See also *Visual function.*
Developmental disorders, pervasive, **567–578**. See also *Autism.*
Developmental follow-up, in preterm neonate, 1109
Developmental milestones, birth to 2 years, 512–513
Developmental outcome, in extreme prematurity, **937–953**
Developmental screening, instruments for, 472
Developmental testing, in mental retardation, 511
Deviation, vertical, with infantile esotropia, 743
Dexamethasone, for bacterial meningitis, 350
for tuberculosis in infancy, 1098
Diabetes mellitus, and hypertension, 159–160
blood pressure and lipids in, 47
insulin-dependent, hypertension in, **93–104**
Diabetic ketoacidosis, **355–363**
clinical manifestations of, 356
fluid resuscitation in, 348
management of, 360–361
pathophysiology of, 355–356
stabilization of, 356–360
transport in, indications for, 357
special considerations in, 362
Diabetic nephropathy, and hypertension, 94–96
definition of, 95
effect of hypertension treatment on, 98–100
Diaphragm, development of, 1317
Diaphragmatic hernia, congenital, as newborn surgical emergency, 1315–1325
associated anomalies with, 1317–1318
diagnosis of, 1320
differential diagnosis of, 1320–1321
embryology of, 1316–1317
extracorporeal membrane oxygenation for, 1325–1326
follow-up on, 1328–1329
future therapies for, 1329
history of, 1315
incidence of, 1315–1316
management of, 1321–1325
ECMO, 1325–1326
prenatal, 1322
preoperative, 1322–1323
surgical, 1324–1325
pathophysiology of, 1318–1319
chest radiograph of, 1321
extracorporeal membrane oxygenation with, 1013
surfactant replacement therapy for, 930
Diarrhea, in appendicitis, 1204
Diastolic function, in hypertension, 52–53
Diazepam, for increased muscle tone, 598
in developmental disabilities, 594
intubation with, 388
Diazoxide, for hypertension, in infancy, 118–119
for hypertensive emergency, 207
Diet, and childhood blood pressure, 181–183
and hypertension, in infancy, 113
effect on adolescent hypertension, 83
for hypertension, in insulin-dependent diabetes mellitus, 100
in adolescent obesity treatment, 89
Differential reinforcement, in behavior management, 621–622
Digital subtraction angiography, for renal artery stenosis diagnosis, 134–136
intravenous, in persistent hypertension, 173
Diltiazem, for childhood hypertension, 198–200
Disruptive behavior, with developmental disabilities, pharmacology in, 605–611
Diuretics, for hypertension, effect on diabetic nephropathy, 99
in children, 200–201
in infancy, 118
Diving reflex, triggering of, 326–327
Dobutamine, for hemodynamically unstable child, during transport, 267
in shock, 310
pre-heart transplant use of, 1027
Dopamine, for hemodynamically unstable child, during transport, 267
for neonatal cardiopulmonary resuscitation, 298
in shock, 309–310
Doppler ultrasonography, renal, in persistent hypertension, 173
Dorsal rhizotomy, in cerebral palsy, 656
Down syndrome, **523–535**
anticipatory pediatric management in, 529
developmental disabilities associated with, 528–529
diagnosis of, clinical, 525
prenatal, 532
ethical dilemmas in, 532–533

historic perspective on, 523–524
medical problems with, during childhood, 526–528
in newborn period, 525–526
outcome in, 529, 532
pathogenesis of, 524–525
prevalance of, 524
preventive health care in, recommendations for, 530–531
psychiatric disorders with, 586–587
Drowning/near-drowning, **321–336**. See also *Near-drowning*.
definition of, 321
incidence and epidemiology of, 321–324
injuries from, in pediatric population, 1363
monitoring and laboratory tests in, 331–332
outcome in, predictability of, 331
pathophysiology of, 324–331
cardiovascular, 331
neurologic, 330
pulmonary, 330
renal, 331
respiratory reflexes in, sequence of, 326
treatment of, 332–334
Drug abuse, maternal, and developmental disability, 485
Duane's retraction syndrome, strabismus with, 749–750
Dubin-Johnson syndrome, in newborn, and jaundice, 1166
Ductus arteriosus, patent, and systemic hypertension, 145
Dyslexia, associated disorders with, 876
classification of, 874–875
diagnosis of, 875–876
dynamics of, 873–878
genetics of, 873–874
incidence and definitions of, 869–870
neuroanatomic correlates of, 874
neurophysiologic correlates of, 874
treatment of, 876–877
controversial, 877
patient management in, 877–878
Dysrhythmias, in diabetic ketoacidosis, stabilization and management of, 358
Dystonia, treatment of, 602–603

Early intervention, for developmental disability, implications of, 486–488
Ears, minor anomalies of, syndromes associated with, 469
Echocardiography, for hypertension, in infancy, 116–117
Ectopia lentis, secondary glaucoma with, 864
Edema, effects on airway resistance, 385
Educational deprivation, and reading failure, 871
Educational intervention, in autism, 574
Educational therapy, in learning disabilities, 499–500
Eisenmenger's syndrome, and systemic hypertension, 145
Electroencephalogram, in developmental delay, 473
Electroretinogram, 667–668
Ely's test, of rectus femoris tightness, in cerebral palsy, 651
Emergency medical technician-paramedic course, in neonatal transport, 279
Emesis, for iron poisoning, 417
Emotional deprivation, and reading failure, 871
Emotional disorder, and reading failure, 871
Emotional disturbances, with learning disabilities, 496–497
Emotional problems, with cerebral palsy, 544
Enalapril, for hypertension, in children, 195–198
renin-angiotensin system associated, 73
Encephalopathy, hypoxic-ischemic, and developmental disability, 483–484
neuroimaging findings in, 474
neurological compromise with, 344
End-stage renal disease, sonographic appearance of, 170
Endocrine abnormalities, with Down syndrome, 527
Endocrine causes, of hypertension, in children, **149–164**
in infancy, 112–113
Endocrine disease, eyelid edema with, 794–795
Endomyocardial biopsy, for rejection surveillance, in heart transplantation, 1036, 1038
Endorectal pull-through procedure, for inflammatory bowel disease, 1223–1225
Endoscopy, in inflammatory bowel disease, 1219–1220
Endotoxins, gastrointestinal, and necrotizing enterocolitis, 1051
Endotracheal intubation, for newborns, 296
for shock, pre-transport, 306
for upper airway obstruction, during transport, 268
interhospital transport with, 271–272
Endotracheal tube(s), loss of, in transport, 314
pediatric sizes of, 376

Enterocolitis, necrotizing, **1047–1059**
pathogenesis of, 1048–1054
epidemiologic studies of, 1048
immature gastrointestinal host defenses in, 1048–1050
preventive strategies for, 1053–1056
corticosteroids, 1053–1055
feeding regimens, 1055
inflammatory mediator agonists for, 1056
oral immunoglobulins for, 1055–1056
Entropian, keratitis with, 764
Environment, and neonatal outcome, 293
of premature infant, developmental interventions in, 947–948
Environmental toxins, and cerebral palsy, 541–542
Epinephrine, for hemodynamically unstable child, during transport, 267
for neonatal cardiopulmonary resuscitation, 298
in shock, 309–310
Epiphora, with infantile glaucoma, 856
Esmolol, properties of, 202
Esodeviations, of eyes, 741–745
Esophageal atresia, as newborn surgical emergency, 1289–1293
associated defects in, 1291
embryology of, 1289–1290
evaluation of, 1291–1292
management of, 1292–1293
outcome in, 1293
pathology of, 1290
Esophageal perforation, from birth trauma, 1354
Esotropia, accommodative, 743–745
infantile, 742–743
Essential hypertension, childhood
prevention of, **179–194**. See also under *Hypertension*.
Ethambutol, for tuberculosis in infancy, 1095–1096
Ethionimide, for tuberculosis in infancy, 1096
Ethylene glycol, intoxication with, management of, 418–419
Etomidate, intubation with, 388, 390
Executive function, deficits in, with learning disabilities, 495
Exercise, and blood pressure, 37
effect on adolescent hypertension, 83
in adolescent obesity treatment, 89
Exercise testing, in childhood hypertension, 54–55
Exodeviations, of eyes, 745–747
Exotropia, constant, 746
intermittent, 745–746
Expositions, premature infants at, 227–229
Exposure, for examination, in trauma patient, 366–367
Extinction, in behavior management, 620–621
Extracorporeal Life Support Organization, 1005
Extracorporeal membrane oxygenation, **1005–1022**
alternative therapies to, 1014
as bridge to heart transplantation, 1027
consequences of, evaluation of, 1020
cut point criteria for, 1008, 1019
decision making in, 1019–1022
delayed, morbidity from, 1011
efficacy of, 1011–1012
for congenital diaphragmatic hernia, 1325–1326
survival in, 1326–1328
for meconium aspiration syndrome, 974
for persistent pulmonary hypertension of newborn, 988–990
future of, 1012–1014
changes in patients, 1013–1014
changes in technique, 1012–1013
improved pumps and circuits for, 1013
morbidity from, 1009
outcomes with, 1014
patient selection for, 1011
predicting need and choosing best test for, 1006–1007
surfactant replacement therapy with, 931
survival rate in, 1013
unnecessary, avoidance of, 1008–1011
utilization rate for, 1006–1007
venovenous catheterization for, 1012
Extremely low birthweight infant, maturational factors compromising, 946–947
Extremities, injuries to, transport and stabilization in, 373
minor anomalies of, syndromes associated with, 469
Eye(s), chemical burns of, treatment of, 836
esodeviations of, 741–745
examination of, in developmental disability, 468
exodeviations of, 745–747
foreign bodies in, initial management of, 829–830
injuries to, **827–839**
evaluation of, 827–828
initial management of, 828–836
ophthalmia neonatorum vs, 721
secondary glaucoma with, 865
sports-related, prevention of, 836–838
injury to, and visual problems, 663
minor anomalies of, syndromes associated with, 469

neuronal and vascular development in, 659–660
protection of, glasses for, 671
Eyelid(s), anatomy of, 790
droopy, 797–802
edema of, 789–797
allergic disorders and, 792–793
inflammatory, 790–794, 794
noninflammatory, 795–797
infection of, and inflammatory edema, 790–791
injuries to, initial management of, 828–829
movement of, in tear drainage, 769
pyogenic granuloma of, 1200
swollen, as sign of systemic disease, **789–804**
tumors of, 808–810
clinical signs of, 805–806
diagnostic approaches to, 807
therapeutic approaches to, 807
Eyewear, sports, protective, 837
manufacturers of, 838

Face, hemangioma of, 1185, 1186, 1190
minor anomalies of, syndromes associated with, 469
Facial tic, ocular disorders with, 764
Falls, injuries from, in pediatric population, 1364
Family survival, in developmental disabilities, 676–677
Fats, dietary, and childhood blood pressure, 182–183
Fatty acids, beta-oxidation of, inborn errors of, and apparent life-threatening events, 905–906
Feeding disorders, in traumatic brain injury, 559
with autism, 572
Feeding regimens, for necrotizing enterocolitis prevention, 1055
Felodipine, for childhood hypertension, 198–200
Femoral anteversion, assessment of, in cerebral palsy, 650
Femoral shortening, examination for, in cerebral palsy, 647
Fentanyl, intubation with, 388–389
Fetal alcohol syndrome, psychiatric disorders with, 587
Fetal distress, and need for resuscitation, 290
with meconium staining, 958–959, 968
Fetal heart tones, intrapartum monitoring of, 291
Fever, in appendicitis, 1205
in tuberculosis in infancy, 1089
Fiberoptic intubation, 397–398
Fibromuscular dysplasia, and hypertension, renin-angiotensin system in, 71–72
and renal artery stenosis, 124
persistent hypertension with, 174–175
Fine motor skills, developmental milestones in, 512–513
Fixation, in vision assessment, 695–696
Fixed-wing transport(s), cost of, 452
mileage and time to patient with, 450
mileage and time to receiving facility with, 451
Flank pain, in appendicitis, 1205
Fluid overload, in transport, 314
Fluid retention, generalized, and eyelid edema, 795
Fluid therapy, in shock, pre-transport, 307
Fluoxetine, for attention-deficit hyperactivity disorder, 611
in developmental disabilities, 595
Fluphenazine, in developmental disabilities, 595
for self-injurious behavior, 604
Focal nodular hyperplasia, of liver, in infancy and childhood, 1265–1266
Foley catheter(s), pediatric sizes of, 376
placement of, in shock, 311
Following, in vision assessment, 695–696
Foot, musculoskeletal examination of, in cerebral palsy, 652
venous anomalies of, 1198
Forearm, blood flow in, correlation with insulin resistance, 85
Fosinopril, for childhood hypertension, 195–198
Fourth nerve palsy, paralytic strabismus with, 748
Fragile X syndrome, psychiatric disorders with, 587
Fresh water, aspiration of, effects of, 328–329
Fructosemia, in newborn, and jaundice, 1165
Furosemide, for hypertension, in infancy, 118

Gait, analysis of, in cerebral palsy, 653–654
Galactosemia, in newborn, and jaundice, 1165
neonatal screening for, 1077–1078
treatment of, 1078
Gastric lavage, for iron poisoning, 417
for tricyclic antidepressant intoxication, 414

Gastrocnemius contracture, examination for, in cerebral palsy, 652
Gastroesophageal reflux, in children, **1233–1251**
classification of, 1236
clinical presentation of, 1236–1237
complications of, 1243
diagnostic evaluation of, 1237–1240
esophageal pH monitoring, 1239–1240
nuclear scan, 1238
upper gastrointestinal endoscopy, 1239
upper gastrointestinal series, 1237–1238
differential diagnosis of, 1238
mechanisms of, 1234–1235
medical therapy for, conservative, 1241
pharmacologic, 1241–1242
surgical therapy with, 1240–1242
normal preventive mechanism, 1234
pathophysiology of, 1234–1236
surgical therapy for, 1242–1248
in preterm neonate, 1107–1108
Gastrointestinal anomalies, as newborn surgical emergencies, 1289–1307
Gastrointestinal decontamination, for acute poisoning, 408
Gastrointestinal disorders, in preterm neonates, 1106–1107
with Down syndrome, 528
Gastrointestinal host defenses, immature, in necrotizing enterocolitis, 1048–1050
Gastroschisis, as newborn surgical emergency, 1310–1312
associated defects with, 1310
embryology of, 1310
evaluation of, 1310–1311
management of, 1311–1312
outcome in, 1312
pathology of, 1310
ultrasonography of, 1311
Gastrostomy, for gastroesophageal reflux, antireflux procedure with, 1246–1247
Genetic disorders, and cerebral palsy, 541
and visual problems, 662
neuroimaging findings in, 474
Genetic factors, and hypertension, 4–5
in infancy, 113
in childhood blood pressure, 180
Genetic material, analysis of, in antenatal detection of surgical anomalies, 1279–1281
Genitalia, minor anomalies of, syndromes associated with, 469
Gilbert's syndrome, in newborn, 1164
Glasgow coma score, in increased intracranial pressure, assessment during transport, 270
in traumatic brain injury, 554–557
modifications for children, 346
Glasses, for children, indications for, 670–671
Glaucoma, **855–867**
anterior cleavage syndromes in, 861–862
congenital, ophthalmia neonatorum vs, 721
infantile, 855–861
clinical evaluation of, 860
clinical signs of, 856–859
epidemiology and genetics of, 859–860
management of, 860–861
pathogenesis of, 859
prognosis in, 861
signs and symptoms in, differential diagnosis of, 856
secondary, in children, 861–862
Globe, ruptured, initial management of, 835–836
Glomerular filtration, reduced, with converting enzyme inhibitor therapy, 198
Glomerulonephritis, chronic, and persistent hypertension, 168
Glucocorticoid excess, exogenous, and hypertension, 156–157, 160
Gordon Armstrong incubator, for neonates, 222
Granulocytic sarcoma, of orbit, 825
Gross motor skills, developmental milestones in, 512–513
Group home, for developmentally disabled, 679–680
Growth deficits, with cerebral palsy, 544
Growth failure, in inflammatory bowel disease, 1217–1218
Growth parameters, with developmental disability, examination for, 468

Haab's striae, with infantile glaucoma, 858
Haddon matrix, of injury causation, 1361
Hair, minor anomalies of, syndromes associated with, 469
Haloperidol, for self-injurious behavior, 604
for Tourette syndrome, 601
in developmental disabilities, 595
Hamartoma, mesenchymal, in infancy and childhood, 1265–1266
Hamstrings, contracture of, in cerebral palsy, orthopedic intervention for, 655
examination of, in cerebral palsy, 650–651
Handling, of premature infant, developmental interventions in, 948

Head, minor anomalies of, syndromes associated with, 469
Head injury, interhospital transport for, 264
  patient stabilization in, for air transport, 453
  shock with, 311–312
  traumatic, acute management of, 557
    types of, 554
Headaches, ocular signs in, 761–763
Hearing, in preterm neonate, 1109
  loss of, with Down syndrome, 526
  measuring/monitoring of, reasons for, 470
Heart disease, congenital, with Down syndrome, 527
  cyanotic, chronic, and systemic hypertension, 145
  ischemic, family history of, correlation with childhood high blood pressure, 38
Heart failure, with proliferative phase hemangiomas, 1185
Heart transplantation, **1023–1046**
  age of recipients, 1024
  donor evaluation for, 1031–1032
  echocardiography of, 1036
  fetal listing of, 1031
  graft coronary artery disease in, 1039
  growth and development with, 1040–1042
  immunizations in, 1042
  immunosuppression for, 1033–1035
  indications for, 1024
  infectious complications in, 1039–1040
  lymphoproliferative disorders in, 1040
  neurodevelopment in, 1041
  orthotopic, 1032
  postoperative management of, 1032–1033
  priority list for, 1031
  recipients of, evaluation of, 1027–1029
    exclusions of, 1029–1030
    order sheet for, 1028
  rejection in, echocardiography of, 1036–1037
    incidence of, 1036
    prevention and treatment of, 1034
    surveillance for, 1036–1038
  ventricular growth and function in, 1038–1039
  waiting list for, 1030–1031
Height problems, with Down syndrome, 526
Helicopter transport, advantages and disadvantages of, 250
  cost of, 452
  mileage and time to patient with, 450
  mileage and time to receiving facility with, 451
Hemangioendothelioma, hepatic, in infancy and childhood, 1263–1265
Hemangioma(s), and vascular malformations, **1177–1200**
  capillary, of orbit, 822
  cavernous, in infancy and childhood, 1265
  cellular characteristics of, 1182–1183
  choroidal, 818
  clinical presentation and natural history of, 1179–1180
  current management of, 1186–1190
    observation and local care, 1186–1189
    pharmacologic therapy, 1187–1188
    surgical therapy, 1190
  hematologic manifestations of, 1184
  of face, 1185, 1188, 1190
  of thigh, 1189
  phases of, 1185
  proliferative phase, complications of, 1184–1186
  radiographic appearance of, 1183–1184
  skeletal manifestations of, 1184
  vascular malformation vs, 1179–1184
Hematologic abnormalities, in preterm neonate, 1110
  with Down syndrome, 528
Hemifacial spasm, ocular disorders with, 764
Hemodynamic abnormalities, in insulin-dependent diabetes mellitus, hypertension with, 96–98
Hemodynamically unstable child, interhospital transport of, 266–268
Hemolysis, in newborn, and jaundice, 1163
Hemoperitoneum, from birth trauma, 1355
Hemorrhage, control of, in trauma patient, 370
  with proliferative phase hemangiomas, 1186
Hemothorax, from birth trauma, 1354
Hepatic hemangioendothelioma, in infancy and childhood, 1263–1265
Hepatic injury, from birth trauma, 1355
Hepatic toxicity, with acetaminophen poisoning, 409
Hepatic tumors, in infancy and childhood, 1263–1269
  benign, 1263–1266
    focal nodular hyperplasia, 1266
    hepatic adenoma, 1266
    mesenchymal hamartoma, 1265–1266
    vascular, 1263–1265
  malignant, 1266–1269
    hepatoblastoma, 1267–1268
    hepatocellular carcinoma, 1268–1269
    incidence of, 1267
    sarcoma, 1269

Hepatitis, in newborn, and jaundice, 1168
Hepatoblastoma, in infancy and childhood, 1267–1268
Hepatocellular carcinoma, in infancy and childhood, 1268–1269
Hernias, inguinal, **1121–1131**. See also *Inguinal hernias.*
Herpes infection, in newborn, and jaundice, 1168
Hess Premature Infant Ambulance, 231
Heterophoria, definition of, 740
Heterotropia, definition of, 740
High-risk infant, **479–490**
  rehabilitation therapy for, 633–635
Hip, in cerebral palsy, musculoskeletal examination of, 647–650
    subluxation/dislocation of, orthopedic intervention for, 654–655
Hirschsprung's disease, as newborn surgical emergency, 1299–1301
    embryology of, 1299
    evaluation of, 1300
    management of, 1300–1301
    outcome in, 1301
    pathology of, 1299
Homework, in learning disabilities, 500
Homocystinuria, neonatal screening for, 1079–1080
Hormonal treatment, of cryptorchidism, 1137–1138
Horner syndrome, and ptosis, 800
Hot soaks, for staphylococcal conjunctivitis, 760
Hydralazine, for hypertension, childhood, 206
    in infancy, 118–119
  for hypertensive emergency, 207
Hydrocarbons, ingestion of, 420–422
    clinical manifestations of, 421
    pathophysiology of, 420–421
    treatment of, 421–422
Hydrocele, forms of, 1122
Hydrochlorothiazide, for hypertension, in infancy, 118
Hydroxylase deficiencies, and hypertension, 154–155
Hyperactivity, with developmental disabilities, 583
Hyperaldosteronism, and hypertension, 153–154, 160
    renin-angiotensin system in, 72
Hyperbilirubinemia, in neonatal period, direct, 1164–1172
    indirect, 1162–1164
  in preterm neonate, 1108
Hypercalcemia, and hypertension, 157–158, 160
Hyperinsulinemia, and development of hypertension, 84, 86
Hypermineralocorticoidism, and hypertension, 152, 154–156, 160
Hyperopia, glasses for, 670
  school complaints with, 763
Hyperosmolar states, in diabetic ketoacidosis, cerebral edema with, 359
Hypertension, adolescent obesity and, **81–92**
  adult, childhood predictors for, **23–40**
      discussion of, 34–38
      methods used for, 23–24
      population used for, 23–27
      statistical methods in, 24–25
    correlations with childhood levels, 27
    family history and, 35
    predictive factors for, 31–34
  and lipid abnormalities, epidemiology of, 42–43
  childhood, atherosclerosis and, 55–56
    cardiovascular manifestations of, **51–59**
    correlation with adult blood pressure, 27–31
    correlation with adult Quetelet index, 33, 36
    diagnostic tests for, 129
    diastolic function in, 52–53
    electrocardiographic changes in, 51–52
    endocrine causes of, **149–164**
    exercise testing in, 54–55
    future perspectives on, 57
    genetic factors in, **1–11**
    left ventricular morphology in, 53–54
    persistent, renal imaging in, **165–178**
    pharmacologic management of, **195–212**
    predictive factors for future high blod pressure in, 31–34
    renal artery stenosis and, 129–130
    renovascular disorders and, 175
    solitary kidney and, 130
    structural adaptations in, 55–56
    systolic function in, 53–54
    vascular reactivity in, 56–57
  development of, in obesity, 82–87
  dexamethasone-suppressible, 155
  essential, childhood prevention of, **179–194**
      high-risk approaches to, 187–190
      population approaches to, 185–187
        educational, 185–186
        environmental, 186–187
      recommendations for, 190–191
      strategies for, 184
    childhood risk factors for, 179–184
    renin-angiotensin system in, 72
  familial aggregation of, 3–4
  family history of, correlation with childhood high blood pressure, 38

genetics of, 1, 4–5, 98
in infancy, **105–122**
blood pressure standards in, 107
causes of, 107–114
definition and incidence of, 106–107
diagnostic studies of, 114–117
evaluation of, 114–117
management of, 117–120
measurement techniques in, 105–106
prognosis for, 120
stepwise therapy for, 119
in insulin-dependent diabetes mellitus, **93–104**
prevention of, 98–100
treatment of, 100
renin-angiotensin system associated, treatment of, 73–74
renovascular, **123–140**
in children. See also *Renovascular hypertension.*
secondary, in children, causes of, 128–129
systemic, cardiovascular causes of, **141–147**
treatment of, effect on diabetic nephropathy, 98–100
interaction with lipids, 46–47
twin studies of, 5–10
Hypertensive emergencies, antihypertensive drugs for, 207
Hyperthermia, in near-drowning, role of, 328
Hyperthyroidism, and hypertension, 158, 160
eyelid edema with, 795
Hyperventilation, for increased intracranial pressure, 347–348
intubation for, 385
Hyphema, traumatic, appearance of, 833
treatment of, 834
Hypnotics, intubation with, 387–390
Hypochlorhydria, and necrotizing enterocolitis, 1049
Hypoglycemia, and developmental disability, 484
in transport, 314
Hyponatremia, seizures with, management of, 349
Hypopituitarism, in newborn, and jaundice, 1166
Hypoplastic left heart syndrome, heart transplantation for, 1023–1024
implantation of, 1033
pretransplant management of, 1026
ultrasonography of, 1025
Hypotension, in shock, 304
Hypothermia, and neonatal outcome, 293
in transport, 314
Hypothyroidism, and hypertension, 158–160
congenital, neonatal screening for, 1073, 1076–1077
eyelid edema with, 794–795
in newborn, and jaundice, 1164
Hypotropia, with ocular trauma, 746
Hypovolemia, cardiovascular response to, 369
intubation with, 394
Hypoxia, in near-drowning, duration of, 328
Hypoxic-ischemic brain damage, **1061–1072**. See also *Brain damage.*
Hypoxic-ischemic encephalopathy, and developmental disability, 483–484
neuroimaging findings in, 474
neurological compromise with, 344

Icterus, nonhemolytic, familial, in newborn, 1163–1164
Iliopsoas, tightness of, examination for, in cerebral palsy, 649
Imaging studies, noninvasive, in persistent hypertension, 172–173
Imipramine, for attention-deficit hyperactivity disorder, 609–610
Imitation training, in behavior management, 622–623
Immersion syndrome, definition of, 321
Immune-mediated diseases, and eyelid edema, 793
Immunizations, in preterm neonate, 1109–1110
Immunoglobulins, oral, for necrotizing enterocolitis prevention, 1055–1056
Immunologic deficiencies, gastrointestinal, and necrotizing enterocolitis, 1049
Immunosuppression, for inflammatory bowel disease, agents for, 1222
in heart transplantation, 1033–1035
effect on growth and development, 1041
shock in, 305
Imperforate anus, in newborn, 1304
Incubator(s), early, for neonates, 223
for premature infant, 227
Infant(s), blindness in, 777–780
extremely low birthweight, maturational factors compromising, 946–947
failed vision test in, 754
heart transplantation in, **1023–1046**. See also *Heart transplantation.*
high-risk, **479–490**
rehabilitation therapy for, 633–635
hypertension in, **105–122**. See also under *Hypertension.*

Infant(s) *(Continued)*
tuberculosis in, in the 1990s, **1087–1103**. See also *Tuberculosis*.
vision development in, **693–703**
Infections, and cervical lymphadenopathy, 1154
and eyelid edema, 794
Infectious agents, gastrointestinal, and necrotizing enterocolitis, 1050–1051
Infectious complications, in heart transplantation, 1039–1040
Infectious diseases, and visual problems, 662
in newborn, and jaundice, 1167
Inflammatory bowel disease, **1213–1231**
clinical features of, 1215–1218
extraintestinal manifestations, 1216–1217
malnutrition and growth failure, 1217–1218
presentation, 1215–1216
definitions and classifications of, 1213
diagnosis of, 1218–1220
endoscopy, 1219–1220
laboratory evaluation, 1218–1219
radiology, 1220
epidemiology of, 1212–1214
etiology of, 1214
nutritional therapy for, 1222
operative intervention for, 1223–1227
pathogenesis of, 1213–1215
pathology of, 1215
prognosis in, 1227–1228
treatment of, 1220–1227
pharmacologic therapy, 1221–1222
Inflammatory mediators, and necrotizing enterocolitis, 1051, 1056
Inguinal hernia(s), **1121–1131**
clinical features of, 1123
contralateral exploration of, 1123–1124
embryology and pathology of, 1121–1122
forms of, 1122
in girls, 1127
in premature infant, 1108, 1126
in preterm neonate, 1108
incidence and risk factors in, 1122
irreducible, 1124–1125
operative considerations in, 1125
recurrent, 1126–1127
Insect bite, and eyelid edema, 793
Instructional training, in behavior management, 622–623
Insulin, increased levels of, and coronary artery disease risk, 44
interaction with blood pressure and lipids, 44–45
therapy with, and sodium retention, 97
Insulin resistance, in obesity, and development of hypertension, 82, 84
Intensive care units, mobile, for neonates, 235–236
Interests, repertoire of, in autism, 569
Interferon, subcutaneous, for hemangiomas, 1187–1188
Intestinal atresia, as newborn surgical emergency, 1293–1296
associated defects with, 1295
embryology of, 1293
evaluation of, 1295
management of, 1295–1296
outcome in, 1296
pathology of, 1294
Intestinal lengthening, for short bowel syndrome, 1344–1346
Intestinal motility, poor, and necrotizing enterocolitis, 1049
Intestinal pacing, for short bowel syndrome, 1343
Intestinal permeability, in preterm infant, and necrotizing enterocolitis, 1049
Intestinal resection, massive, physiologic response to, 1337–1338
Intestinal tapering, for short bowel syndrome, 1343–1344
Intestine, in preterm infant, host defense deficiencies in, 1050
Intra-abdominal injury, from birth trauma, 1355–1357
Intracranial hemorrhage, and developmental disability, 482
risk of, with extracorporeal membrane oxygenation, 1013
Intracranial pressure, increased, in neurologically compromised child, management of, 347
interhospital transport with, 270–271
intubation with, 393–394
Intracranial pressure-volume relationship, in neurologically compromised child, 338–339
Intraocular foreign body, initial management of, 835
Intraocular tumors, 813–821
clinical signs of, 806
diagnostic approaches to, 807
medulloepithelioma, 817–818
therapeutic approaches to, 808
Intraosseous fluid infusion, in shock, 307
Intrathoracic injury, from birth trauma, 1354
Intratracheal suctioning, of newborns, universal vs selective, 962–965
Intrauterine growth retardation, and developmental disability, 482–483
Intrauterine infection, neuroimaging findings in, 474
Intravenous catheter, pediatric sizes of, 376

Intraventricular hemorrhage, effect of surfactant administration on, 927–929
neuroimaging findings in, 474
Intubation, awake, 386–387
clinical situations requiring special consideration, 393–394
fiberoptic, 397–398
for congenital diaphragmatic hernia, 1322
in neonatal cardiopulmonary resuscitation, 294–296
indications for, 384–386
lightwand assisted, 398–399
retrograde, 399
sequence in, 395–397
special techniques in, 397–400
tactile, 398
technique of, decision-making in, 392–393
tube selection and placement in, 397
with muscle relaxants, 390–392
with sedative-hypnotics, 387–390
Ion transport, alterations in, in insulin resistance, hypertension with, 86
Ipecac, for tricyclic antidepressant intoxication, 414
Iris, injuries to, initial management of, 832–833
Iron, poisoning with, 415–418
clinical manifestations of, 417
pathophysiology of, 416–417
treatment of, 417–418
Ischemia-reperfusion injury, and necrotizing enterocolitis, 1052–1053
Isoniazid, for tuberculosis in infancy, 1095–1096
Isoproterenol, for hemodynamically unstable child, during transport, 267
Isradipine, for childhood hypertension, 198–200

Jaundice, in newborn, **1161–1175**
breast-milk, 1162–1163
causes of, 1162
physiologic, 1161–1162
Jejunostomy, for gastroesophageal reflux, 1247
Joint Commission on Accreditation of Healthcare Organizations, monitoring of neonatal resuscitation by, 432–433

Kaposi's sarcoma, conjunctival, 813–814
of eyelid, 809
Kasabach-Merritt phenomenon, 1189
Keratitis, herpes simplex, conjunctivitis vs, 759
Kernicterus, and developmental disability, 484
Ketamine, intubation with, 388–389
Ketoacidosis, diabetic, **355–363**. See also *Diabetic ketoacidosis.*
Kidney. See also under *Renal.*
solitary, and hypertension, 130
Klippel-Trenaunay syndrome, of leg, 1198
Knee, musculoskeletal examination of, in cerebral palsy, 650–652
Kyphosis, abnormal, in cerebral palsy, orthopedic intervention for, 655–656

Labetolol, for childhood hypertension, 205
for hypertensive emergency, 207
Lacerations, from birth trauma, 1352
Lacrimal drainage system, anatomy of, 770
disorders of, 771–776
atresia of lacrimal puncta, 771
congenital mucocele of lacrimal sac, 771–772
congenital obstruction of, 772–776
Lacrimal puncta, atresia of, 771
Lacrimal sac, congenital mucocele of, 771–772
Lacrimal system apparatus, disorders of, **767–776**
Lamellar cataract, 843–844
Langerhan's cell histiocytosis, of orbit, 826
Language disorders, written, accommodations for, 500
Language skills, developmental milestones in, 512–513
Language therapy, in autism, 574
Larygoscope blades, pediatric sizes of, 376
Laser therapy, for hemangiomas, 1188–1189
for retinopathy of prematurity, 711
Learning disabilities, **491–505**
deficits associated with, 495–497
definition of, 491–492
diagnostic criteria for, 494–495
early identification of, 493–494
in adolescence, 502
intervention in, 499–502
nonstandard therapy for, 501–502
outcome in, 503
pathogenesis of, 494
pediatric assessment in, 497–498
periodic reevaluations of, 502–503
psychoeducational testing in, 498–499
rehabilitation therapy for, 639–640
subtypes of, 492–493
Leber's congenital amaurosis, and infant blindness, 778–779

Left coronary artery, anomalous origin of, heart transplantation for, 1026–1027
Left ventricle, growth and function of, in heart transplantation, 1038–1039
hemodynamics of, racial differences in, 18
hypertrophy of, in heart transplantation, echocardiography of, 1036
morphology of, in hypertension, 53–54
Leg(s), capillary-lymphatic lesions of, 1193
combined capillary-lymphatico-venous anomaly of, 1198
Leg length discrepancy, examination for, in cerebral palsy, 652–653
Lens, basic anatomy of, 842
injuries to, initial management of, 833–834
Leptomeningeal cyst, of scalp, 1159–1160
Leukemia, and cervical lymphadenopathy, 1155
and eyelid edema, 796
ocular tumor with, 821
Leukocoria, with retinoblastoma, 806, 814, 816
Levodopa, for dystonia, 602–603
Lidocaine, for hemodynamically unstable child, during transport, 267
Life-threatening events, apparent, in sudden infant death syndrome, 900–906
conditions causing, 905–906
diagnosis of, 900–903
documented monitoring of, 903–904
event recordings of, 903–904
management of, 903–905
outcome in, 905
Lightwand assistance, in intubation, 398–399
Lip, venous malformation of, 1196
Lipids, abnormalities of, and hypertension, epidemiology of, 42–43
effect of hypertension treatment on, 46–47
interaction with insulin and blood pressure, 44–45
relationship to blood pressure, **41–49**
lifestyle factors in, 45–46
Lipoproteins, in adolescent obesity, 88
Lisch nodules, with neurofibromatosis, 819–820
Lisinopril, for childhood hypertension, 195–198
Lithium countertransport, and childhood hypertension, 2
Liver, injury to, from birth trauma, 1355
Longitudinal cohort, childhood predictors for adult hypertension in, 23–24, 26
Lorazepam, for increased muscle tone, 598–599
intubation with, 388
Lordosis, abnormal, in cerebral palsy, orthopedic intervention for, 655–656
Louis-Bar syndrome, 1193
Lowe syndrome, secondary glaucoma with, 864
Lower airway obstructive disease, interhospital transport with, 269
Lower esophageal sphincter, dysfunction of, **1233–1251**
Lundeen, Evelyn, as neonatal nurse, 231–232
Lung disease, chronic, and developmental disability, 485
Luteinizing hormone releasing hormone, for cryptorchidism, 1138
Lymph nodes, involvement of, in tuberculosis in infancy, 1096
Lymphadenopathy, of neck, 1153–1155
Lymphangioma, of neck, 1156
of orbit, 822–824
Lymphatic malformations, 1194
of neck, 1195
Lymphedema, and eyelid edema, 796
Lymphoma, and cervical lymphadenopathy, 1155
of orbit, 826
Lymphoproliferative disorders, in heart transplantation, 1040

Macroalbuminuria, definition of, 95
Macula densa cells, in renin-angiotensin system, 66–67
Malignant tumors, and eyelid edema, 796
Malnutrition, in inflammatory bowel disease, 1217–1218
Malrotation, as newborn surgical emergency, 1296–1299
embryology of, 1296–1297
evaluation of, 1297–1298
management of, 1298
outcome in, 1298–1299
pathology of, 1297
Mania, with developmental disabilities, 581
Mannitol, for increased intracranial pressure, in neurologically compromised child, 348
Mantoux test, for tuberculosis in infancy, 1092
Maple syrup urine disease, neonatal screening for, 1078–1079
Marfan syndrome, secondary glaucoma with, 864
Maternal drug abuse, and developmental disability, 485
Maternal factors, and hypertension, in infancy, 113

Maturational factors, compromise of, in extremely low birthweight infant, 946–947
Mechanical ptosis, 801–802
Meconium, aspiration of, in utero vs postpartum, 959–960
definition of, 956
Meconium aspiration syndrome, **955–981**
adjunctive therapies for, 974–975
animal models of, 976
chest physiotherapy for, 971
continuum of, 965–966
conventional mechanical ventilation for, optimal strategy for, 972–973
extracorporeal membrane oxygenation for, 974
high-frequency ventilation for, 973
in apparently healthy neonate, 962
incidence of, 960
intratracheal suctioning for, 971
long-term sequelae of, 975–976
medicolegal considerations in, 968–970
negative-pressure ventilation for, 974–975
obstetric interventions in, 958–962, 965–968
pathology of, 960–961
pathophysiology of, 956–958
pediatric interventions for, benefit of, 958–962
effectiveness of, 961–962
pneumonia with, surfactant replacement therapy for, 930
postmortem findings in, 961
prevention of, 970
saline lavage for, 971–972
surfactant therapy for, 973–974
systemic steroid treatment for, 975
unresolved issues in, 965–976
with thin-consistency meconium, 962
Meconium ileus, as newborn surgical emergency, 1305–1307
evaluation of, 1305–1306
management of, 1306
outcome in, 1306
pathology of, 1305
Meconium plug syndrome, as newborn surgical emergency, 1306–1307
Meconium staining, **955–981**
chest physiotherapy for, 971
continuum of, 965–966
delivery room management of, recommendations for, 964
fetal distress with, 958–959
medicolegal considerations in, 968–970
routine intubation with, danger of, 963
tracheal suctioning with, omission of, outcome with, 963–965
Medical care, in developmental disabilities, 678–679
Medical control, in critical care transport, 243–244
Medications, and hypertension, in infancy, 113
for newborn cardiopulmonary resuscitation, 296–298
Medulloepithelioma, intraocular, 817–818
Melanocytoma, of optic disc, fundus photograph of, 818
Melanocytosis, congenital, conjunctival, 812
Memory, deficits in, with learning disabilities, 496
Meningitis, bacterial, neurological compromise with, 343
Menopausal gonadotropin, human, for cryptorchidism, 1137
Mental retardation, **507–521**
and reading failure, 871
behavior management in, 516–517
behavioral disorders with, clinical issues in, 580–581
deficits associated with, 509–510
definition of, 508
developmental milestones in, 514
developmental testing in, 511
diagnostic testing in, 511, 514
differential diagnosis of, 510
early intervention in, 516
educational programs for, 516
etiologies of, 514
financial assistance in, 518
general pediatric care in, 515–516
genetic counseling in, 518
intervention strategies for, 515–518
levels of, 508–509
parental counseling in, 517–518
pediatric assessment for, 510–511
prevalence of, 509
psychiatric symptoms with, clinical issues in, 580
psychological testing in, 514–515
sports, social, and recreational activities in, 517
transition to adulthood in, 518–519
with autism, 572
with cerebral palsy, 543
Mental stress, and blood pressure, 37
Metabolic disorders, and visual problems, 662
screening for, **1073–1085**
current programs for, 1075–1083
principles of, 1074
specimen collection for, 1074–1075
Metabolic factors, in childhood blood pressure, 180
Metabolic screening, in developmental delay, 474–475

Methanol, intoxication with, management of, 419–420
Methohexital, intubation with, 388
Methylphenidate, for attention-deficit hyperactivity disorder, 606
in developmental disabilities, 595
Methylprednisolone, for spinal cord injury, 350
in heart transplantation, 1034
Metoprolol, properties of, 202
Metronidazole, for inflammatory bowel disease, 1222
Microalbuminuria, and hypertension, 95
Microcephaly, and developmental disability, 484
neuroimaging findings in, 474
Midazolam, intubation with, 388–389
Mineralocorticoids, excess, and hypertension, 152, 154–156, 160
Mini-residency, in neonatal transport, 278
Minoxidil, for childhood hypertension, 206–207
for hypertensive emergency, 207
Mitral regurgitation, and systemic hypertension, 145
Mobility equipment, for developmental disabilities, 632
Mobius syndrome, ptosis with, 798
strabismus with, 751
Molecular genetics, in antenatal detection of surgical anomalies, 1280–1281
Monoamine oxidase inhibitors, for attention-deficit hyperactivity disorder, 611
Monoclonal antibodies, for immunosuppression, in heart transplantation, 1035
Morbidity, in extreme prematurity, improvement in, with surfactant treatment, 942–943
Morphine, intubation with, 388–389
Motor development, in extreme prematurity, 941
Motor disorders, developmental, pharmacology in, 593–603
in traumatic brain injury, 558
Motor vehicle accidents, injuries from, in pediatric population, 1362
Mouth, minor anomalies of, syndromes associated with, 469
Movement disorders, with developmental disabilities, treatment of, 599–603
Mucocele, congenital, of lacrimal sac, 771–773
Multiple Risk Factor Intervention Trial, cholesterol and blood pressure in, 43
Munchausen's syndrome by proxy, and apparent life-threatening events, 906
Muscle relaxants, for airway management, during transport, 401
intubation with, 390–392, 395
reversal of, with intubation, 392
Muscle tone, increased, pharmacologic treatment of, 597–599
Muscular dystrophy, and ptosis, 801
rehabilitation therapy for, 639
Musculoskeletal abnormalities, with Down syndrome, 527–528
Musculoskeletal examination, in cerebral palsy, 645–654
Mutihandicapped children, education of, 888
Myasthenia gravis, and ptosis, 800–801
Mycobacterial culture, for tuberculosis in infancy, 1094
Mycobacterial infection, and cervical lymphadenopathy, 1154
Myelomeningocele, rehabilitation therapy for, 637–638
Myoclonus, with developmental disabilities, treatment of, 600
Myokymia, ocular disorders with, 764
Myopathic ptosis, 800–801
Myopia, glasses for, 670
Myotonic dystrophy, and ptosis, 801

Nadolol, properties of, 202
Naloxone, for neonatal cardiopulmonary resuscitation, 298
Narcotics, intubation with, 388–389
maternal administration of, and heavy meconium staining, 967
Nasogastric tube(s), pediatric sizes of, 376
placement of, in shock, 311
Nasolacrimal duct, obstruction of, and eyelid edema, 791
congenital, 772–776
dacrocystorhinostomy for, 776
irrigation of, 775–776
probing of, 775
silicon tube intubation for, 776
ophthalmia neonatorum vs, 722
Nasolacrimal duct system, anatomy of, 770
in tear drainage, 769–770
Nasolacrimal sac, massage of, for nasolacrimal duct obstruction, 774
National Cholesterol Education Program, 43
National Conferences on Cardiopulmonary Resuscitation, guidelines for neonatal life support, 431
National Task Force on Neonatal Resuscitation, guidelines of, 432

Near-drowning. See also *Drowning/near-drowning*.
age at, 323
definition of, 321
laboratory values after, 329
locations of, 324
month of, 325
outcomes of, 323
Neck, lymphadenopathy of, 1153–1155
lymphatic anomaly of, 1194
masses of, **1151–1160**
evaluation of, 1151–1152
specific lesions, 1152–1159
unusual, 1158–1159
minor anomalies of, syndromes associated with, 469
Necrotizing enterocolitis, **1047–1059**. See also under *Enterocolitis*.
Negative reinforcement, in behavior management, 623
Neomucosa, in short bowel syndrome, 1344
Neonatal care, innovation in, 236–237
nationwide, spread of, 234–235
Neonatal resuscitation, criteria for, 435
evaluation of, 434–435
procedures for, 288–289
quality assessment and management in, 436
standards for, assessing adherence to, **431–438**
transport criteria in, 278–279, 436
Neonatal transport, for specialized services, 280–281
historical perspectives of, **221–239**
on-site education in, 279–280
outreach educational program for, **275–285**
background on, 275–276
evaluation of, 281–284
format for, 278–280
objectives of, 276–277
staff for, 277–278
posttransport feedback in, 280
provisional diagnoses in, 265
regionalization of, rise and decline of, 224–227
return transport in, 281
skill workshop in, 279
Neonate, heart transplantation in, **1023–1046**. See also *Heart transplantation*.
Neonatology, advances in, pediatrician's view of, **1105–1114**
Nephrectomy, for renovascular hypertension, 138
Nephroblastoma, 1253–1257. See also *Wilms' tumor*.
Nephropathy, in insulin-dependent diabetes mellitus, prevention and treatment of, 98–100
reflux, and hypertension, in children, 167–168
Neuro-ophthalmologic conditions, pediatric, **777–788**
Neuroblastoma, and eyelid edema, 796
in infancy and childhood, 1257–1263
clinical manifestations of, 1258–1259
diagnosis of, 1259
etiology and incidence of, 1257–1258
staging of, 1259–1261
treatment of, 1261–1263
metastatic, of orbit, 826
Neurodevelopmental examination, abnormal, and developmental disability risk, 485
Neurodevelopmental outcome, in extreme prematurity, 942
Neurodevelopmental therapy, for developmental disabilities, 630–631
Neurofibroma, of eyelid, 810
Neurofibromatosis, and renal artery stenosis, persistent hypertension with, 175
optic glioma with, 783–784
Neurogenic tumors, of neck, 1156–1157
Neuroleptics, for attention-deficit hyperactivity disorder, 611
Neurologic assessment, in neurologically compromised child, 345–346
in trauma patient, 366
Neurologic compromise, causes of, 338
central nervous system osmolality in, 339–340
initial evaluation and management of, 344–350
initial resuscitation in, 346–347
intracranial pressure-volume relationship in, 338–339
laboratory and radiologic studies in, 350
neurologic assessment in, 345–346
neurologic stabilization in, 347–350
pathophysiologic considerations in, 338–344
transport in, **337–354**
Neurologic disorders, in renovascular hypertension, 125
Neuropathic ptosis, 799–800
Neurorehabilitation, in traumatic brain injury, 558–561
Neurosurgery, in cerebral palsy, 547
Neurotransmitters, in central nervous system, 596
Nevus, conjunctival, 812
melanocytic, of eyelid, 810
uveal, 819–820
Nevus flammeus, of eyelid, 808–809
Newborn(s), cardiopulmonary resuscitation of, application to transport medicine, **287–302**

Newborn(s) *(Continued)*
jaundiced, **1161–1175**. See also *Jaundice.*
management of, issues related to, 434
persistent pulmonary hypertension of, treatment advances in, **983–1004**. See also *Pulmonary hypertension.*
Newborn surgical emergencies, **1289–1314**, **1315–1333**. See also *Surgical emergencies.*
Nicardipine, for childhood hypertension, 198–200
Nifedipine, for childhood hypertension, 198–200
for hypertensive emergency, 207
Night sweats, in tuberculosis in infancy, 1089
Nimodipine, for childhood hypertension, 198–200
Nissen fundoplication, for gastroesophageal reflux, 1243–1244
Nitric oxide, and developing pulmonary circulation, 992–994
endogenous, metabolism of, 991
for congenital diaphragmatic hernia, 1323
inhaled, for persistent pulmonary hypertension of newborn, 991–997
animal studies of, 994–995
effects on blood gases, 996
hemodynamic effects of, 995
human studies of, 995–997
toxicity of, 997
reduced production of, effect of, 993
synthesis and action of, 991–992
Nitroprusside, for hemodynamically unstable child, during transport, 267
for hypertension, in infancy, 118–119
for hypertensive emergency, 207
pre-heart transplant use of, 1027
Noonan's syndrome, ptosis with, 798
Norepinephrine, for hemodynamically unstable child, during transport, 267
in shock, 309–310
Nose, minor anomalies of, syndromes associated with, 469
Nurse educator, for neonatal transport educational program, 277–278
Nursing course, in neonatal transport, 278
Nutrition, in short bowel syndrome, 1338–1339
problems in, in preterm neonates, 1106–1107
therapy with, for inflammatory bowel disease, 1222
Nystagmus, acquired, 782–783
with headache, 761
congenital, 780–782
latent, 782
neurologic disorders in, 780–783
optokinetic, assessment of, 696–698
evaluation for, 666–667
see-saw, with craniopharyngioma, 784
with intracranial neoplasm, 783

Obesity, adolescent, and cardiovascular risk, 87–88
and hypertension, **81–92**
and childhood blood pressure, 180–181
and insulin resistance, development of hypertension in, 84
childhood, treatment of, 88–90
definition of, 81–82
role in cardiovascular risk, 45
Obstruction, with proliferative phase hemangiomas, 1185–1186
Occlusion, for amblyopia, 732–734
Occupational therapy, for developmental disabilities, 632–633
in cerebral palsy, 546–547
Octreotide acetate, for short bowel syndrome, 1340
Ocular anomalies, evaluation of, by pediatrician, 665–666
Ocular disorders, and reading failure, 872–873
Ocular injuries, **827–839**. See also *Eye(s), injuries to.*
Ocular signs and symptoms, in childhood, **753–766**
Ocular tumors, **805–826**
clinical signs of, 805–806
congenital, secondary glaucoma with, 865
diagnostic approaches to, 807
therapeutic approaches to, 807–808
Oculo-dento-osseous dysplasia, secondary glaucoma with, 862–863
Oculomotor disorders, and reading failure, 872–873
Oculomotor nerve, lesions of, and ptosis, 799–800
Omeprazole, for short bowel syndrome, 1339–1340
Omphalocele, as newborn surgical emergency, 1307–1310
associated defects with, 1308
embryology of, 1307
evaluation of, 1308–1309
management of, 1309–1310
outcome in, 1310
pathology of, 1308
Ophthalmia neonatorum, **715–725**
differential diagnosis of, 716–721
epidemiology of, 715–717
etiologic considerations in, 721–722
prevention of, 722

treatment of, 716
Ophthalmic problems, with Down syndrome, 526
Ophthalmologic follow-up, in preterm neonate, 1108–1109
Ophthalmologist, pediatric, common interventions by, 670–671
Opiate antagonists, for self-injurious behavior, 604–605
Opioid agents, for short bowel syndrome, 1340
Optacon, use by blind children, 886–889
Optic atrophy, with headache, 761
Optic glioma, 824
and visual loss, 783–784
Optic nerve, cupping of, with infantile glaucoma, 858–859
hypoplasia of, and infant blindness, 778–779
injuries to, initial management of, 835
melanocytoma of, 816–817
tumor of, and visual loss, 783
Optic neuritis, and visual loss, 785–786
Optokinetic nystagmus, assessment of, 696–698
evaluation for, 666–667
Orbital cellulitis, eyelid edema with, 794
Orbital emphysema, initial management of, 829–830
Orbital fractures, initial management of, 830
Orbital hemorrhage, initial management of, 829–830
Orbital injuries, findings in, 828
Orbital tumors, 821–826
clinical signs of, 806
diagnostic approaches to, 807
therapeutic approaches to, 808
Organic amblyopia, 730
Organomegaly, with developmental disability, examination for, 468
Organophosphates, poisoning with, 422–423
Organ(s), growth and development of, renin-angiotensin system and, 68–69
transplantation of, blood pressure and lipids in, 47
Oropharyngeal problems, with Down syndrome, 527
Orthopedic management, of cerebral palsy, 547, **645–657**. See also *Cerebral palsy*.
Orthophoria, definition of, 740
Orthotics, for developmental disabilities, 631–632
Osmolality, in diabetic ketoacidosis, calculation of, 356
Osteoma, choroidal, 818–819
Overcorrection, in behavior management, 625–626
Oxygen, administration of, in transport, 382–383
effect on cerebral blood flow, in neurologically compromised child, 341
for shock, pre-transport, 306
for upper airway obstruction, during transport, 268
Oxygen cylinder, duration of, 272
Oxygen exchange, in newborn, improvement with chronic nitric oxide inhalation, 997
Oxygen mask, pediatric sizes of, 376
Oxygen radicals, and necrotizing enterocolitis, 1052–1053
Oxygen tension, neonatal, postductal, effect of nitric oxide on, 996

Pancuronium, intubation with, 391–392
Papilledema, with headache, 761
Papilloma, conjunctival, 812
Para-amino salicylic acid (PAS), for tuberculosis in infancy, 1096
Paraldehyde, for status epilepticus, 349
Parental interview, in behavior analysis in developmental disabilities, 618–619
Parental reactions, to developmental disabilities, 682
Parenting skills, in developmental disabilities, 677
Parotid masses, 1157–1158
Partially sighted children, education of, 887–888
Patent ductus arteriosus, pulmonary hemorrhage with, 924
with surfactant replacement therapy, 925
Patient restraint, during transport, 272–273
Pattern-evoked visual potentials, assessment of, 700–701
Pedestrian injuries, in pediatric population, 1363
Pediatric cataracts, **841–853**. See also *Cataracts*.
Pediatric critical care, transport program for, **241–261**
communication in, 251, 257
equipment for, 247–249
financial issues in, 256
medical-legal issues in, 252–256
liability, 256
receiving institution responsibilities, 253–254
referring institution responsibilities, 255–256
safety protocols, 254
standards for, 254
transport agreements, 252–253
medications list for, 248

Pediatric critical care *(Continued)*
mobilization time for, 257–258
modes of transportation in, 248–251
one-way vs two-way, 241–242
paradigm for, 256–259
patient stabilization in, 258
personnel for, 243–244
physician role in, 244, 246–247
protocols for, 246
regional considerations in, 242
team composition for, 245–247
team training for, 245
transport log for, 251–252
Pediatric neuro-ophthalmologic conditions, **777–788**
Pediatric trauma, causes of death from, 1360
prevention strategies for, **1359–1368**
Pediatrician, role in reading disorders, **869–879**. See also *Reading disorders.*
Pelvic injuries, transport and stabilization in, 372–373
Pelvis, musculoskeletal examination of, in cerebral palsy, 646–647.
Pemoline, for attention-deficit hyperactivity disorder, 606
Pentothal, intubation with, 388
Percutaneous transluminal angioplasty, for persistent hypertension, 176
for renovascular hypertension, in children, 135–137
Perinatal care, regionalization of, and neonatal transport, 275
Periorbital cellulitis, with eyelid infection, 790–791
Periorbital trauma, and eyelid edema, 795–796
Peripheral nerve injury, from birth trauma, 1352–1354
Peritoneal dialysis, inguinal hernias with, 1126
Persistent pulmonary hypertension, of newborn, treatment advances in, **983–1004**. See also *Pulmonary hypertension.*
Peter's anomaly, secondary glaucoma with, 862
pH, effect on cerebral blood flow, 341
Phacomatoses, secondary glaucoma with, 863–864
Pharmacotherapy, for childhood hypertension, **195–212**
for psychiatric disorders with developmental disabilities, 589
for renovascular hypertension, 135
in autism, 575
in cerebral palsy, 546
in developmental disabilities, **593–616**
in learning disabilities, 501
Pharynx, injury to, from birth trauma, 1353–1354
obstetrician suctioning of, value of, 963
Phenobarbital, for status epilepticus, 349
Phenylketonuria, neonatal screening for, 1073, 1075–1076
treatment of, 1076
Phenytoin, for status epilepticus, 349
Pheochromocytoma, and hypertension, 150–151, 160
Phlebothrombosis, in venous malformation, 1194
Photophobia, glasses for, 671
ocular disorders with, 764
with infantile glaucoma, 856
Phrenic nerve palsy, from birth trauma, 1353
Physical activity, and childhood blood pressure, 183
role in cardiovascular risk, 45
Physical appearance, with Down syndrome, 526
Physical disorders, and reading failure, 871–872
Physical therapy, for developmental disabilities, 632–633
in cerebral palsy, 546–547
Pierre Robin sequence, secondary glaucoma with, 865
Pilocytic astrocytoma, juvenile, of orbit, 824
Pilomatricoma, of scalp, 1159
Pimozide, for Tourette syndrome, 601
in developmental disabilities, 595
Pindolol, properties of, 202
Plasma renin activity, and hypertension, in infancy, 115
in renal artery stenosis, 131–132
Platelet-activating factor, and necrotizing enterocolitis, 1051
Pleural effusion, in tuberculosis in infancy, 1090
Pneumogram, in sudden infant death syndrome, 901–903
Pneumonia, infectious, congenital, surfactant replacement therapy for, 930
Pneumoperitoneum, from birth trauma, 1356–1357
Pneumothorax, from birth trauma, 1354
Poisoning, acute, transport management in, **407–430**
suspected, management of, 350
Poisonings, injuries from, in pediatric population, 1364
Polycystic kidney disease, in persistent hypertension, 171
Polycythemia, and developmental disability, 484
Polysomnography, in sudden infant death syndrome, 902–903

Popliteal angle, assessment of, in cerebral palsy, 651
Port-wine stains, 1191–1192, 1200
Positioning, of infant, therapy for, 635
of premature infant, developmental interventions in, 948
Positive pressure ventilation, in neonate, indications for, 294
Positive reinforcement, in behavior management, 619–620
Potassium, dietary, and childhood blood pressure, 181–182
Pragel incubator, 234
Prazosin, for hypertension, in insulin-dependent diabetes mellitus, 100
Preauricular cysts/sinuses, 1153
Prednisone, in heart transplantation, 1034
Preferential looking, evaluation of, 668–669
Preferential viewing, assessment of, 698–700
Pregnancies, screening of, for surgical anomalies, 1273–1276
maternal serum alpha-fetoprotein for, 1274
ultrasonography for, 1274–1276
Premature infant(s), at expositions, 227–229
care of, in Illinois, 233–234
hematologic problems and monitoring in, 1110
immunizations in, 1109–1110
incubator care of, beginning of, 227
ophthalmologic follow-up in, 1108–1109
response to stress by, 947
Prematurity, and cerebral palsy, 539–540
and developmental disability, 480–482
apnea of, and sudden infant death syndrome, 906–907. See also *Apnea.*
extreme, developmental interventions for, 947–949
integration of parents in, 949
outcome in, **937–953**
improved, 949
optimizing of, 945
impairment in, risk factors for, 944
morbidity across time in, 940–942
physical growth in, 938–939
rate of handicap in, 940
surfactant for, economic impact of, 944–945
mortality in, 938
untimely transition in, 945
interhospital transport for, 264
retinopathy of, **705–714**. See also *Retinopathy of prematurity.*
Prenatal abnormalities, and cerebral palsy, 540–541
Preoxygenation, in intubation, 395
Proctocolectomy, for inflammatory bowel disease, 1223
Professional Air Transport Association, 455
Propranolol, for hypertension, childhood, 203
in infancy, 118
properties of, 202
Prostaglandins, for hemodynamically unstable child, during transport, 267
for persistent pulmonary hypertension of newborn, 988
Proteinuria, with converting enzyme inhibitor therapy, 198
Pseudoesotropia, 741
Pseudoptosis, 802
Pseudotumor, orbital, idiopathic inflammatory, eyelid edema with, 794
Psychiatric disorders, classification of, 579–580
with developmental disabilities, **579–592**
clinical issues in, 580–581
specific syndromes of, 586–588
symptom cluster approach to, 581–586
treatment of, 588–590
Psychological testing, in mental retardation, 514–515
Psychosis, with developmental disabilities, 581–583
Psychosocial issues, in traumatic brain injury, 561
Psychotherapy, for psychiatric disorders with developmental disabilities, 588–589
Ptosis, acquired, 799–802
mechanical, 801–802
myopathic, 800–801
neuropathic, 799–800
traumatic, 802
congenital, 797–798
with systemic disease, 798
Pulmonary artery, acetylcholine-stimulated, effect of oxygen tension on, 993
Pulmonary circulation, developing, nitric oxide and, 992–994
Pulmonary diseases, surfactant replacement therapy for, **913–936**
Pulmonary distress, causes of, and outcome, 970
Pulmonary edema, in near-drowning, pathophysiology of, 329
with sea water inhalation, 328
Pulmonary hemorrhage, with surfactant replacement therapy, 924–925
Pulmonary hypertension, neonatal, high-frequency ventilation for, 986
intravenous vasodilators for, 987–988
persistent, calcium channel blockers for, 988
extracorporeal membrane oxygenation for, 988–990
developmental follow-up on, 1010

Pulmonary hypertension *(Continued)*
nitric oxide for, 991–997
prostaglandins for, 988
tolazoline for, 987
treatment of, advances in, **983–1004**
without extracorporeal membrane oxygenation, follow-up on, 1009
Pulmonary hypoplasia, surfactant replacement therapy for, 930
Punishment, in behavior management, 623–624
Pyelonephritis, chronic, and persistent hypertension, in children, 168
Pyogenic granuloma, conjunctival, 812–813
of eyelid, 1200
Pyrazinamide, for tuberculosis in infancy, 1096
Pyridoxine, for tuberculosis in infancy, 1095

Quetelet index, of risk for future high blood pressure, 31–33

Racial aspects, of blood pressure, **13–22**
Radioactive plaque, scleral application of, 816
Ramipril, for childhood hypertension, 195–198
Reading, disorders of, pediatrician's role in, **869–879**
failure in, secondary, causes of, 870–873
headache caused by, 762
Record-keeping, in behavior management, 626
Rectus femoris, assessment of, in cerebral palsy, 651
Red eye, 756–761
Refractive amblyopia, 730
treatment of, 731–732
Refractive error(s), and headache, 762
asymmetric, glasses for, 670–671
Rehabilitation, for developmental disabilities, **629–643**
Reimer's migration percentage, of hip subluxation, in cerebral palsy, 649
Reinforcement, in behavior management, differential, 621–622
negative, 623
positive, 619–620
Renal arteriography, for renovascular hypertension, 136
Renal artery, thromboembolic occlusion of, in persistent hypertension, 171
Renal artery stenosis, and hypertension, in children, 129–130
in infancy, 115
renin-angiotensin system in, 71
causes of, 124–125
fibromuscular dysplasia and, in persistent hypertension, 174–175
in children, blood pressure in, 126–127
evaluation for, 127–135
neurofibromatosis and, in persistent hypertension, 175
Renal biopsy, percutaneous, imaging-assisted, for persistent hypertension, 169
Renal disease, blood pressure and lipids in, 47
diabetic, and hypertension, 94–96
Renal failure, chronic, and hypertension, renin-angiotensin system in, 72–73
Renal function studies, split, for renal artery stenosis diagnosis, 130–131
Renal hemodynamics, modulation of, renin-angiotensin system and, 69
Renal hypoplasia, and renal artery narrowing, 124
Renal imaging, for persistent hypertension, **165–178**
nucleotide scans, for renal artery stenosis diagnosis, 133–134, 136
ultrasonography, for renovascular hypertension, 136
Renal parenchymal disease, and persistent hypertension, 168–172
Renal trauma, and renal artery narrowing, 124
Rendu-Osler-Weber syndrome, 1192
Renin, in renin-angiotensin cascade, 62–64
plasma, 115, 131–132
renal vein activity of, selective, for renal artery stenosis diagnosis, 132–133, 136
secretion of, physiologic mechanisms regulating, 67
Renin-aldosterone pathway, 152
abnormalities of, and hypertension, 153
Renin-angiotensin-aldosterone system, racial differences in, 18
Renin-angiotensin system, and blood pressure regulation, in infancy and childhood, **61–79**
during development, 61–66
regulation of, 66–68
role of, 68–69
in hypertension, clinical situations in, 71–73
experimental models of, 70–71
Renovascular disease, and persistent hypertension, 172, 175
prevalence of, 123–124
Renovascular hypertension, in childhood, **123–140**

clinical characteristics of, 125–127
evaluation of, 130–136
history in, 128
physical examination in, 129
treatment of, 135–139
in infancy, 108–111
Renovascular surgery, for hypertension, in infancy, 118
Respiration, control of, in extremely low birthweight infant, 946
stabilization of, in air transport, 452
in diabetic ketoacidosis, 357
Respiratory distress, in shock, 305
interhospital transport for, 264
Respiratory distress syndrome, high-frequency ventilation for, 986
in preterm neonate, 1109
Respiratory failure, impending, intubation for, 384
stabilization of, in air transport, 453
Respiratory reflexes, in drowning, sequence of, 326
Respiratory system, in sudden infant death syndrome, 899
Respiratory therapy course, in neonatal transport, 279
Response cost, in behavior management, 625
Retardation, mental, **507–521**. See also *Mental retardation.*
Retina, ablative therapy of, for retinopathy of prematurity, 711
astrocytic hamartoma of, 816
fundus photograph of, 817
capillary hemangioma of, 814–816
fundus photograph of, 817
injuries to, initial management of, 835
Retinal pigment epithelium, congenital hypertrophy of, 820
Retinoblastoma, computed tomography of, 815
fundus photography of, 815
gross section of, 815
intraocular, 813–814
leukocoria with, 806, 814, 816
strabismus with, 739
Retinopathy of prematurity, **705–714**
age of onset of, 710
clinical course of, 708–710
incidence of, 705–707
international classification of, 708–709
pathophysiology of, 706–708
prevention of, 707–708
secondary glaucoma with, 865
sequelae of, 712–713
severity of, 708
therapeutic interventions for, 711–712
timecourse of, 709–710
Retrograde intubation, 399
Rett syndrome, psychiatric disorders with, 587–588
Revascularization surgery, for renovascular hypertension, 137–139
Reye's syndrome, mannitol for, 348
Rhabdomyosarcoma, of neck, 1157
of orbit, 825
Rhizotomy, dorsal, in cerebral palsy, 656
Rifampin, for tuberculosis in infancy, 1095–1096
Right lower quadrant, disorders of, **1201–1211**
Right ventricle, dysfunction of, following heart transplantation, 1028–1029
Rigidity, pharmacologic treatment of, 597
Ringer's solution, infusion of, in shock, 308
Rotor's syndrome, in newborn, and jaundice, 1166
Rubella, and cataracts, 842, 844
congenital syndrome of, secondary glaucoma with, 865

Saethre-Chotzen syndrome, ptosis with, 798
Salicylate intoxication, 410–413
clinical manifestations of, 411–412
pathophysiology of, 411
pharmacology of, 410–411
treatment of, 412–413
Saline lavage, for meconium aspiration syndrome, 971–972
Salt, intake of, and hypertension, 2
sensitivity to, racial differences in, 17–18
Sarcoma, hepatic, in infancy and childhood, 1269
Scalp, cephalohematoma of, 1159
dermoid cyst of, 1159
growing fracture of, 1159–1160
masses of, **1151–1160**
pilomatricoma of, 1159
Schizophrenia, with autism, 572
School complaints, ocular findings with, 763
School problems, in traumatic brain injury, 560–561
Scoliosis, in cerebral palsy, examination for, 646–647
orthopedic intervention for, 655–656
Sea water, aspiration of, effects of, 328–329
Sedative(s), for transport, **381–406**
and airway management, 400–401
intubation with, 387–390
reversal of, with intubation, 390
Segal, Sydney, as innovator in neonatal care, 236–237
Seizure disorders, with autism, 572
with cerebral palsy, 544

Seizures, interhospital transport for, 264, 270–271
management of, 349
Selective vulnerability, concept of, in hypoxic-ischemic brain damage, 1070–1071
Self-injurious behavior, with developmental disabilities, pharmacology in, 603–605
Self-stabilization, of premature infant, facilitation of, 948–949
Sensory deficits, in traumatic brain injury, 559
with cerebral palsy, 544
Sepsis, interhospital transport for, 264
shock in, 305
Serotonin agonists, for self-injurious behavior, 605
Sex hormones, and hypertension, 157, 160
Shaping, in behavior management, 621–622
Shock, diagnosis of, 304–305
etiology of, 303–304
evaluation, treatment, and transport of, **303–319**
monitoring of, 311
stabilization of, in trauma patient, 368–370
stages of, 304
transport in, equipment for, 313
mode of, 312–313
stabilization for, 306–312
treatment and complications in, 312–314
with head injury, 311–312
Short bowel syndrome, in pediatric population, **1335–1350**
clinical management of, 1338–1347
etiology of, 1336–1337
medical therapy for, 1338–1340
nutrition, 1338–1339
pharmacologic agents, 1339–1340
prognosis in, 1347
surgical therapy for, 1340–1347
indications for, 1340–1341
intestinal lengthening, 1344–1346
intestinal pacing, 1343
intestinal tapering, 1343–1344
neomucosa, 1344
options in, 1341
reversed segments and interpositions, 1342–1343
small bowel transplantation, 1346–1347
valves in, 1342
Sickle cell disease, neonatal screening for, 1080–1081
SIDS. See *Sudden infant death syndrome.*
Silicon tube intubation, for nasolacrimal duct obstruction, 776
Sixth nerve palsy, paralytic strabismus with, 748–749
paretic strabismus with, 787
Skin, minor anomalies of, syndromes associated with, 469
problems with, with developmental disability, 468
with Down syndrome, 527
Sleep, disturbances of, with autism, 572
studies of, in sudden infant death syndrome, 901–903
Small bowel transplantation, for short bowel syndrome, 1346–1347
Small for gestational age, and developmental disability, 482–483
Small left colon syndrome, as newborn surgical emergency, 1307
Smith-Lemli-Opitz syndrome, ptosis with, 798
Social communication, disorders of, with developmental disabilities, 586
Social interaction, in autism, 569
Social skills, adaptive, developmental milestones in, 512–513
deficits in, with learning disabilities, 496
training in, for psychiatric disorders with developmental disabilities, 589–590
with learning disabilities, 501
Sodium, chronic retention of, in hyperinsulinemia, hypertension with, 86
dietary, and childhood blood pressure, 181
sensitivity to, and childhood hypertension, 2–3
Sodium bicarbonate, for neonatal cardiopulmonary resuscitation, 298
for salicylate intoxication, 412
for tricyclic antidepressant intoxication, 415
Soft tissue injury, as birth trauma, 1351–1352
Soleus contracture, examination for, in cerebral palsy, 652
Solumedrol, in heart transplantation, 1034
Somatoform disorders, with developmental disabilities, 585
Spasmus nutans, nystagmus in, 782
Spasticity, pharmacologic treatment of, 597
Special education, in developmental disabilities, 678–679
Speech therapy, in cerebral palsy, 547
Spinal cord injury, management of, 350
neurological compromise with, 342
Spinal tap, contraindications to, 349
Spine, in cerebral palsy, deformity of, orthopedic intervention for, 655–656
musculoskeletal examination of, 646

minor anomalies of, syndromes associated with, 469
Spironolactone, for hypertension, in children, 200–201
in infancy, 118
Spleen, injury to, from birth trauma, 1356
Staheli test, for iliopsoas tightness, in cerebral palsy, 649
Status epilepticus, management of, 349
neurological compromise with, 343–344
Stepwise therapy, for hypertension, in infancy, 119
Stereotypy, with developmental disabilities, 585–586
Sternocleidomastoid tumor, from birth trauma, 1352
Steroids. See also *Corticosteroids*.
for viral conjunctivitis, 760
systemic, for meconium aspiration syndrome, 975
Stickler syndrome, secondary glaucoma with, 865
Stillbirths, apparent, outcomes in, 299
Stimulants, for attention-deficit hyperactivity disorder, 606–608
Strabismic amblyopia, 729
treatment of, 732
Strabismus, **737–752**
and headache, 762–763
correction for, 670
definitions pertaining to, 739–740
diagnosis of, 738–739
nonparalytic, 740–741
paralytic, 747–749
paretic, neurologic disorders and, 786–788
refractive error in, glasses for, 671
school complaints with, 763
surgery for, 751–752
syndromes of, 749–751
with headache, 761
with intraocular tumor, 806
Streptomycin, for tuberculosis in infancy, 1096
Stress, response to, in preterm infant, 947
Stroke, family history of, correlation with childhood high blood pressure, 38
Sturge-Weber syndrome, 1191
secondary glaucoma with, 863
Stylets, pediatric sizes of, 376
Subcortical pathways, in vision development, 694
Subcutaneous fat necrosis, from birth trauma, 1351
Subdural hematoma, computed tomography of, 555
Submersion injury, definition of, 321
Substance-abusing mothers, infants of, sudden infant death syndrome among, 907–908
Succinylcholine, intubation with, 390–391
contraindications to, 394
Suctions, pediatric sizes of, 376
Sudden infant death syndrome, **897–911**
apnea hypothesis of, 899–900
clinical presentation in, 898
grief in, 900
postmortem examination in, 898–899
Sulfasalazine, for inflammatory bowel disease, 1221
Surfactant replacement therapy, **913–936**
administration of, 914–927
agents for, 915–918
complications of, 924–925
equipment for, 916–917
influence on intraventricular hemorrhage, 927–929
methods of, 923
natural extract, 914
prophylactic, 918, 920
randomized controlled trials of, 916
prophylactic, 917
synthetic, 917
synthetic, 915, 917
prophylactic, 917, 919–920
timing of, 918–923
prophylactic vs early rescue, 918–922
single vs multiple doses, 922–923
for meconium aspiration syndrome, 973–974
new applications of, 929–931
with extracorporeal membrane oxygenation, 931
with high-frequency ventilation, 931
Surgical anomalies, pediatric, antenatal diagnosis of, **1273–1287**
follow-up investigations in, 1276–1282
management algorithm for, 1275
Surgical emergencies, in newborn, **1289–1314**, **1315–1333**
Sympathetic nervous system, activation in hyperinsulinemia, hypertension with, 86
in renin-angiotensin system, 67–68
Systemic hypertension, cardiovascular causes of, **141–147**
Systolic function, in hypertension in children, 53–54

Tachycardia, in shock, 304–305
Tactile intubation, 398
Takayasu's arteritis, and systemic hypertension, 145–146
Tear(s), drainage of, 769–771
production of, 768

Tear film, structure of, 767–768
Tearing, abnormalities of, 768–769
with nasolacrimal duct obstruction, 774
Teeth, minor anomalies of, syndromes associated with, 469
Telangiectasias, 1192–1193
Temperature control, during transport, 273
Teratoma, of neck, 1157
of orbit, 822–823
Testicular appendages, torsion of, 1145–1146
Testicular torsion, **1133–1149**
extravaginal, 1141
incidence of, 1142
intravaginal, 1141
neonatal, 1142–1143
prognosis in, 1145
pubertal, 1143–1145
Testis, undescended, position of, 1134
Thal fundoplication, for gastroesophageal reflux, 1243–1244
Therapists, roles and functions of, in rehabilitation for developmental disabilities, 630
Thigh, hemangioma of, 1189
Thioridazine, for self-injurious behavior, 604
in developmental disabilities, 595
Third nerve palsy, paralytic strabismus with, 747–748
Thomas test, for iliopsoas tightness, in cerebral palsy, 649
Thoracic trauma, transport and stabilization in, 371
Thoracotomy, tube, interhospital transport with, 272
Thumb movement, as sign of muscle relaxation, in intubation, 396
Thyroglossal duct cyst, 1152–1153
Thyroid nodules, 1157–1158
Thyroxine, for congenital hypothyroidism, 1077
Time-out, in behavior management, 624–625
Timolol, properties of, 202
Tolazoline, for congenital diaphragmatic hernia, 1323
for hemodynamically unstable child, during transport, 267
for persistent pulmonary hypertension of newborn, 987
TORCH syndrome, and cataracts, 842
Torticollis, 1155–1156
from birth trauma, 1352
Tourette syndrome, treatment of, 600–602
Toxoplasmosis, neonatal screening for, 1083
Tracheostomy, with intubation, 399–400
Transluminal angioplasty, percutaneous, for persistent hypertension, 176
for renovascular hypertension, in children, 135–137
Transport, **221–456**
airway management and sedation for, **381–406**
cardiopulmonary resuscitation of newborns in, **287–302**
for trauma patient, **365–380**
in acute poisoning, management in, **407–430**
life support training for, 245
personnel for, for neonatal transport educational program, 277–278
patient assessment by, 264
program for, organization of, for critical care, **241–261**
provisional diagnoses in, 265
stabilization and management in, **263–274**
Transport abnormalities, and hypertension, 2
Transport log, for critical care transport, 251–252
Trauma patient, diagnosis and initial stabilization in, 367–370
initial management of, 366–367
transport of, **365–380**
communication and referral in, 375, 377
equipment and medications for, 375
Traumatic brain injury, **553–565**. See also *Brain injury.*
Traumatic ptosis, 802
Trichinosis, eyelid edema with, 794
Tricyclic antidepressants, for attention-deficit hyperactivity disorder, 609–610
intoxication with, 413–415
clinical manifestations of, 414
pharmacology of, 413–414
treatment of, 414–415
Trouble shooting, in behavior management, 626
Trypanosomiasis, and eyelid edema, 791
Tuberculin skin test, in tuberculosis in infancy, 1092
Tuberculosis, in infancy, **1087–1103**
BCG vaccination for, prophylactic, 1100
chemoprophylaxis for, 1099
CNS involvement in, 1090
drug resistance in, 1097
drug treatment of, adverse reactions to, 1099
clinical evaluation with, 1099
compliance with, 1097
monitoring of, 1098

in HIV-infected children, clinical presentation of, 1091
drug treatment of, 1098
prevention of, 1099
in the 1990s, children at risk for, 1093
diagnosis of, 1091–1094
epidemiology of, 1087–1088
in immunocompetent infants, clinical presentation of, 1089–1090
perinatally acquired, 1088–1089
radiographic appearance of, 1093
therapy for, 1095–1099
isoniazid prophylaxis for, 1100
lymph node involvement in, 1090
prevention of, 1099–1101
tuberculin skin testing for, 1100
perinatal infection with, antituberculous drugs for, 1096
Tuberous sclerosis, neuroimaging findings in, 474
Tumor(s), and visual problems, 663
Tumor necrosis factor-alpha, and necrotizing enterocolitis, 1051
Tutoring, in learning disabilities, 500
Typing instruction, for blind children, 886
for partially sighted children, 888
Tyrosinemia, in newborn, and jaundice, 1165–1166

Ulceration, with proliferative phase hemangiomas, 1184–1185
Ulcerative colitis, **1213–1231**. See also *Inflammatory bowel disease.*
Ultrasonography, for hypertension, in infancy, 116–117
in antenatal detection of surgical anomalies, 1281–1282
in pregnancy screening for surgical anomalies, 1274
renal, in persistent hypertension, 173
Umbilical anomalies, **1121–1131**
drainage from, 1127–1129
embryology of, 1127
Umbilical artery catheterization, and renovascular hypertension, in infancy, 109
Umbilical hernia, 1129–1130
Umbilical masses, 1129
Upper airway obstruction, interhospital transport with, 268
intubation for, 384–385
relief of, in transport, 383
Upper extremity, in cerebral palsy, deformities of, orthopedic intervention for, 656
musculoskeletal examination of, 652
Upper lid ptosis, with third nerve palsy, 748
Urachus, vestiges of, 1128
Urinary symptoms, in appendicitis, 1204
Urine output, in shock, 311
Urography, intravenous, for hypertension, 167
persistent, 172–173
rapid sequence, for renal artery stenosis diagnosis, 131
Urticaria, and eyelid edema, 792
Uveal melanoma, 820
Uveal nevus, 819–820
Uveitis, secondary glaucoma with, 865

Vancil Ambulance, for neonates, 222
Varicella-zoster, and periorbital cellulitis, 791
Vascular abnormalities, and visual problems, 663
Vascular disease, and hypertension, in infancy, 108–111
Vascular malformation(s), 1190–1199
cellular characteristics of, 1183
classification of, 1177–1179, 1191
biologic, 1178–1179
descriptive and anatomic, 1177–1178
clinical presentation and natural history, 1180–1182
complex-combined, 1197–1198
hemangiomas and, **1177–1200**
hemangiomas vs, 1179–1184
hematologic manifestations of, 1184
radiographic appearance of, 1183–1184
skeletal manifestations of, 1184
Vascular reactivity, in childhood hypertension, 56–57
Vasoactive drugs, for hemodynamically unstable child, during transport, 266–267
Vasoconstriction, in shock, 305
Vasoconstrictors, for conjunctivitis, 761
Vasocontraction, meconium-induced, 968
Vasodilators, for childhood hypertension, 206–207
for congenital diaphragmatic hernia, 1323
intravenous, for persistent pulmonary hypertension of newborn, 987–988
Vasopressin, increased, in diabetic ketoacidosis, cerebral edema with, 359
Vasopressors, for shock, 309–310
Vecuronium, intubation with, 391–392
Venous malformation(s), 1194–1196
of cheek, 1195
of lip, 1196
Venous obstruction, and eyelid edema, 795

Ventilation, assisted, for persistent pulmonary hypertension of newborn, 984–985
conventional mechanical, for meconium aspiration syndrome, 972–973
high-frequency, for meconium aspiration syndrome, 973
for persistent pulmonary hypertension of newborn, 985–987
surfactant replacement therapy with, 931
high frequency oscillating, for congenital diaphragmatic hernia, 1323
in neonatal cardiopulmonary resuscitation, 293–294
negative-pressure, for meconium aspiration syndrome, 974–975
Ventricular tumors, heart transplantation for, 1027
Ventriculoperitoneal shunt, inguinal hernias with, 1126
Verapamil, for childhood hypertension, 198–200
Vernal conjunctivitis, and eyelid edema, 792
VersaBraille, use by blind, 889
Vertical deviations, in strabismus, 746–747
ViewScan, use by visually impaired, 888
Violence, injuries from, in pediatric population, 1365
Viral conjunctivitis, ophthalmia neonatorum vs, 716, 720–721
Viral infections, and cervical lymphadenopathy, 1154–1155
in newborn, and jaundice, 1167–1168
Vision, assessment of, fixation and following in, 695–696
laboratory methods of, 696–701
optokinetic nystagmus, 696–698
pattern-evoked visual potentials, 700–701
preferential viewing, 698–700
development of, **693–703**
anatomic considerations in, 693–694
binocular, 737–738
clinical aspects of, 694–695
failed test of, in childhood, 754–756
neuronal and vascular development in, 659–660
Visual acuity, as function of age, 701
with ocular injuries, 827
Visual development, amblyopia in, 660–661
in developmental disabilities, 660
postnatal, 659–661
Visual evoked potential, testing for, 667–668
Visual function, assessment of, 664–669
ophthalmologist's perspective, 666
pediatrician's perspective, 664–666
in developmental disabilities, **659–674**
Visual impairment, with intraocular tumor, 806
Visual loss, acquired, in childhood, 783–786
craniopharyngioma and, 784–785
optic glioma and, 783–784
optic neuritis and, 785–786
Visual problems, etiology of, 661–664
Visually impaired, and families, working with, **881–890**
as patients, 882–883
attitudes toward, 882
definitions of, 881
early years of, 883–884
educational background on, 884–888
technology for, 888–889
Vitamin supplementation, for preterm neonate, 1106
Vitelline duct, vestiges of, 1128
Vitrectomy, for retinopathy of prematurity, 711–712
Vitreous, hemorrhage of, initial management of, 834
persistent hyperplastic primary, and cataract, 844–845
Volume expanders, for neonatal cardiopulmonary resuscitation, 298
Volume resuscitation, in burn patient, 373
in trauma patient, 370
Vulnerability, selective, concept of, in hypoxic-ischemic brain damage, 1076–1077
Vulnerable child syndrome, 1110

Weight loss, effect on adolescent hypertension, 83
in tuberculosis in infancy, 1089
Weight problems, with Down syndrome, 526
Williams' syndrome, and systemic hypertension, 146
Wilms' tumor, and hypertension, renin-angiotensin system in, 73
in infancy and childhood, 1253–1257
clinical manifestations of, 1254
diagnosis of, 1254–1255
incidence of, 1254
magnetic resonance imaging of, 1255
pathology and staging of, 1255–1256
treatment of, 1256–1257
Wound care, in burn patient, 373–374